Nitrogen heterocyclic compound containing tricyclic ring and use thereof

By developing novel ALK inhibitors with specific aromatic heterocycles and alkyl groups, the problems of resistance to existing ALK, ROS1 and TRK inhibitors and central nervous system toxicity have been solved, and efficient inhibition of ALK kinase mutants and Low toxicity significantly improves the effectiveness of treating non-small cell lung cancer.

WO2024235260A1PCT designated stage expired Publication Date: 2024-11-21MEDSHINE DISCOVERY INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093366
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-25
Filing Date
2024-05-15
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing ALK, ROS1 and TRK inhibitors are prone to drug resistance problems during drug use, and TRKB inhibitors may cause central nervous system toxicity, especially in patients with brain metastatic tumors, and other adverse events such as cognitive impairment.

Method used

A new class of ALK inhibitor compounds has a structure including specific aromatic heterocycles and alkyl groups, which have significant inhibitory activity against ALK kinase mutants and relatively weak inhibition of TRKB kinase, which can avoid central nervous system toxicity, and Good pharmacokinetic properties and tumor-inhibiting effects were shown in vivo.

Benefits of technology

该化合物对ALK激酶突变体具有显著抑制活性,选择性较高,避免了TRKB抑制引起的中枢神经系统毒性,并在体内显示出优异的药效和代谢稳定性,降低了药物相互作用风险。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093366_21112024_PF_FP_ABST
    Figure CN2024093366_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a nitrogen heterocyclic compound containing a tricyclic ring and a use thereof, and particularly a compound represented by formula (II), and a stereoisomer and pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Nitrogen heterocyclic compounds containing tricyclic rings and their applications

[0001] This application claims priority to:

[0002] CN202310562000X, application date: May 16, 2023;

[0003] CN2023108520573, application date: July 12, 2023;

[0004] PCT / CN2023 / 108708, filing date: July 21, 2023;

[0005] CN2023113582584, application date: October 18, 2023;

[0006] CN2024103462896, application date: March 25, 2024. Technical Field

[0007] The present invention relates to a class of nitrogen heterocyclic compounds containing three paracyclic rings and applications thereof, and specifically to a compound represented by formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof. Background Art

[0008] Compared to traditional treatments such as surgery, chemotherapy, and radiotherapy, molecular targeted therapy offers high specificity and low toxicity, and has gradually become the standard treatment for patients with advanced cancer. Kinases are regulators of cell growth, proliferation, and survival, and abnormal regulation leads to cancer.

[0009] ALK (anaplastic lymphoma kinase) is named after its initial discovery in the anaplastic large cell lymphoma AMS3 cell line. Echinoderm microtubule-associated protein-like 4 (EML4) is encoded by the EML4 gene. Non-small cell lung cancer (NSCLC) arises when the N-terminal base region of EML4 fuses with the ALK kinase domain via inversion on the short arm of chromosome 2, forming the EML4-ALK fusion gene.

[0010] ROS1 and ALK are both tyrosine kinase receptors, consisting of an extracellular domain, a transmembrane region, and an intracellular tyrosine kinase active domain. Base deletions in ROS1 lead to the expression of the FIG-ROS1 fusion protein, which activates tyrosine kinase activity and can also lead to the development of NSCLC.

[0011] TRKs are a class of tyrosine kinases activated by nerve growth factor. They include three subtypes: TRKA, TRKB, and TRKC, encoded by the NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1), NTRK2, and NTRK3 genes, respectively. The kinase domains of NTRK1, NTRK2, and NTRK3 share up to 80% sequence homology.

[0012] The three tyrosine kinases mentioned above share strong homology, with ALK and ROS1 sharing up to 77% homology in the ATP binding site of the kinase catalytic region. Sequence homology in the tyrosine kinase region of the ALK, ROS1, and TRKA genes is approximately 40%.

[0013] Currently, marketed ALK, ROS1, and TRK inhibitors have all developed varying degrees of resistance during treatment due to mutations in amino acids within the kinase binding pocket. Common mutations in ALK kinase include G1202R, L1196M, L1198F, G1269A, and I1171N / S / T; common mutations in ROS1 kinase include G2032R and D2033N; and common mutations in TRK kinase include TRKA G595R and TRKC G623R. Furthermore, adverse events associated with CNS-penetrant TRKB inhibitors have been reported, including cognitive impairment, mood disorders, sleep disorders, dizziness, ataxia, and weight gain. Therefore, for patients with brain metastases harboring ALK mutations, improved selectivity for TRKB is needed to avoid CNS toxicity caused by TRKB inhibition. Therefore, the development of novel anti-tumor drugs based on ALK inhibitors that overcome the resistance issues associated with existing small molecule inhibitors and avoid or reduce CNS toxicity is of great clinical value.

[0014] Summary of the Invention

[0015] The present invention provides a compound represented by formula (P), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0016] in,

[0017] T6 and T7 are independently selected from C and N, and are not C or N at the same time, and the 5-membered ring where T6 and T7 are located is an aromatic heterocycle;

[0018] L1 is selected from CH2 and C(=O);

[0019] L is divided by 2 R a Substituted C 1-4 alkyl;

[0020] R1 is selected from O, S and NR4;

[0021] R2 is selected from F, Cl, Br, I, OH, NH2, CN, C 1-4 Alkylamino, -NH-C(O)-C 1-4 Alkyl, C 1-4 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl and C 3-6 Cycloalkyl, the C 1-4 Alkylamino, -NH-C(O)-C 1-4 Alkyl, C 1-4 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl and C 3-6 The cycloalkyl group is optionally substituted by 1, 2 or 3 R d replace;

[0022] Each R3 is independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R b replace;

[0023] R4 is selected from OH, CN and -(OCH2CH2) n -C 1-3 alkoxy;

[0024] n is 0 or 1;

[0025] Ring A is selected from phenyl, 5-6 membered heteroaryl and C 5-6 Cycloalkenyl, the phenyl, 5-6 membered heteroaryl and C 5-6 The cycloalkenyl group is optionally substituted by 1, 2 or 3 R c replace;

[0026] Each R a are independently selected from H, F, Cl, Br, I, OH and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2, or 3 R; or, 2 R a The carbon atom connected to it forms C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl, the C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R;

[0027] Each R b are independently selected from H, F, Cl, Br, I and OH;

[0028] Each R c are independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3The alkyl group is optionally substituted with 1, 2 or 3 halogens;

[0029] Each R d are independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted with 1, 2 or 3 R;

[0030] Each R is independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0031] The present invention also provides a compound represented by formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0032] in,

[0033] is a single bond or a double bond;

[0034] T6 and T7 are independently selected from C and N, and are not C or N at the same time;

[0035] L1 is selected from CH2 and C(=O);

[0036] L is divided by 2 R a Substituted C 1-4 alkyl;

[0037] R1 is selected from O, S and NR4;

[0038] R2 is selected from F, Cl, Br, I, OH, NH2, CN, C 1-4 Alkylamino, -NH-C(O)-C 1-4 Alkyl, C 1-4 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl and C 3-6 Cycloalkyl, the C 1-4 Alkylamino, -NH-C(O)-C 1-4 Alkyl, C 1-4 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl and C 3-6 The cycloalkyl group is optionally substituted by 1, 2 or 3 R d replace;

[0039] Each R3 is independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R b replace;

[0040] R4 is selected from OH, CN and -(OCH2CH2) n -C 1-3 alkoxy;

[0041] n is 0 or 1;

[0042] Ring A is selected from phenyl, 5-6 membered heteroaryl and C 5-6 Cycloalkenyl, the phenyl, 5-6 membered heteroaryl and C 5-6 The cycloalkenyl group is optionally substituted by 1, 2 or 3 R c replace;

[0043] Each R a are independently selected from H, F, Cl, Br, I, OH and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2, or 3 R; or, 2 R a The carbon atom connected to it forms C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl, the C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R;

[0044] Each R b are independently selected from H, F, Cl, Br, I and OH;

[0045] Each R c are independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;

[0046] Each R d are independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted with 1, 2 or 3 R;

[0047] Each R is independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkoxy, C1-3 Alkyl and C 1-3 Halogenated alkyl.

[0048] In some embodiments of the present invention, each R mentioned above is independently selected from H, F, Cl, Br, I, OH, NH2, methoxy, methyl, ethyl, isopropyl, difluoromethyl and trifluoromethyl, and other variables are as defined in the present invention.

[0049] In some embodiments of the present invention, each R mentioned above is independently selected from H, F, OH, methyl and methoxy, and other variables are as defined in the present invention.

[0050] In some embodiments of the present invention, each R mentioned above is independently selected from H, F, OH and methyl, and other variables are as defined in the present invention.

[0051] In some embodiments of the present invention, each R mentioned above is independently selected from H, OH and methyl, and other variables are as defined in the present invention.

[0052] In some embodiments of the present invention, the above R a are independently selected from H, F, CH3 and CF3, and other variables are as defined in the present invention.

[0053] In some embodiments of the present invention, the above R a are independently selected from H and F, and other variables are as defined in the present invention.

[0054] In some embodiments of the present invention, the above two R a The carbon atom to which it is attached forms a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl or N-methylpyrrolidinyl group, and other variables are as defined in the present invention.

[0055] In some embodiments of the present invention, the above two R a The carbon atom to which it is attached forms cyclopropyl and cyclobutyl, and the other variables are as defined in the present invention.

[0056] In some embodiments of the present invention, the above R c are independently selected from F, Cl, Br, I and CH3, wherein CH3 is optionally substituted by 1, 2 or 3 halogens, and other variables are as defined herein.

[0057] In some embodiments of the present invention, the above R c are independently selected from F, Cl, Br, I, CH3 and CF3, and other variables are as defined in the present invention.

[0058] In some embodiments of the present invention, the above R c are independently selected from H and F, and other variables are as defined in the present invention.

[0059] In some embodiments of the present invention, the above R d Each of the following groups is independently selected from H, F, Cl, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl, oxhexyl, piperidinyl and morpholinyl, wherein the methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl, oxhexyl, piperidinyl and morpholinyl are independently optionally substituted with 1, 2 or 3 R, and other variables are as defined herein.

[0060] In some embodiments of the present invention, the above R d Each of the following groups is independently selected from H, F, Cl, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl, oxhexyl, piperidinyl and morpholinyl, wherein the methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl, oxhexyl, piperidinyl and morpholinyl are independently optionally substituted with 1, 2 or 3 R, and other variables are as defined herein.

[0061] In some embodiments of the present invention, the above R d are independently selected from H, F, Cl, C 1-3 Alkyl, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 3-6 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently optionally substituted with 1, 2 or 3 R groups, and the other variables are as defined herein.

[0062] In some embodiments of the present invention, the above R d are independently selected from H, CH3, CF3, CH2CH3, CF2CH3, -CH2OCH3, Other variables are as defined in the present invention.

[0063] In some embodiments of the present invention, the above R d are independently selected from C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 3-6 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently optionally substituted with 1, 2 or 3 R groups, and the other variables are as defined herein.

[0064] In some embodiments of the present invention, the above R dEach of the cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl, oxetanyl, piperidinyl and morpholinyl groups is independently selected from cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl, oxetanyl, piperidinyl and morpholinyl groups, each of which is independently optionally substituted with 1, 2 or 3 R groups, and other variables are as defined herein.

[0065] In some embodiments of the present invention, the above R d are independently selected from cyclopropyl and cyclobutyl, and the cyclopropyl and cyclobutyl are independently optionally substituted by 1, 2 or 3 R, and other variables are as defined in the present invention.

[0066] In some embodiments of the present invention, the above R d are independently selected from Other variables are as defined in the present invention.

[0067] In some embodiments of the present invention, the above R d are independently selected from Other variables are as defined in the present invention.

[0068] In some embodiments of the present invention, the above R d are independently selected from Other variables are as defined in the present invention.

[0069] In some embodiments of the present invention, the above R d are independently selected from Other variables are as defined in the present invention.

[0070] In some embodiments of the present invention, the above L is selected from C 1-4 Alkyl, the C 1-4 The alkyl group is optionally substituted with 1, 2 or 3 F, CH3 or CF3, and the other variables are as defined herein.

[0071] In some embodiments of the present invention, the above L is selected from described Optionally substituted with 1, 2 or 3 F, and other variables are as defined herein.

[0072] In some embodiments of the present invention, the above L is selected from Other variables are as defined in the present invention.

[0073] In some embodiments of the present invention, the above L is selected from Other variables are as defined in the present invention.

[0074] In some embodiments of the present invention, the above L is selected from Other variables are as defined in the present invention.

[0075] In some embodiments of the present invention, the above L is selected from Other variables are as defined in the present invention.

[0076] In some embodiments of the present invention, the above L is selected from Other variables are as defined herein. In some embodiments of the present invention, L1 is selected from CH2, and other variables are as defined herein.

[0077] In some embodiments of the present invention, the above R1 is selected from O, NOH, NCN, NOCH3, NOCH2CH3 and NOCH2CH2OCH3, and other variables are as defined in the present invention.

[0078] In some embodiments of the present invention, the above R1 is selected from O, and other variables are as defined in the present invention.

[0079] In some embodiments of the present invention, the above R2 is selected from F, Cl, Br, I, -NH-CH3, -NH-C(O)-CH3, The -NH-CH3, -NH-C(O)-CH3, Each independently optionally substituted by 1, 2 or 3 R d Substitution, other variables are as defined in the present invention.

[0080] In some embodiments of the present invention, the above R2 is selected from F, Cl, Br, I, -NH-CH3, -NH-C(O)-CH3, Other variables are as defined in the present invention.

[0081] In some embodiments of the present invention, the above R2 is C 2-5 Alkynyl, the C 2-5 Alkynyl is optionally substituted with 1, 2 or 3 R d Substitution, other variables are as defined in the present invention.

[0082] In some embodiments of the present invention, the above R2 is selected from described Each independently optionally substituted by 1, 2 or 3 R d Substitution, other variables are as defined in the present invention.

[0083] In some embodiments of the present invention, the above R2 is selected from Other variables are as defined in the present invention.

[0084] In some embodiments of the present invention, the above R2 is selected from Other variables are as defined in the present invention.

[0085] In some embodiments of the present invention, the above R2 is selected from Other variables are as defined in the present invention.

[0086] In some embodiments of the present invention, the above R2 is selected from Other variables are as defined in the present invention.

[0087] In some embodiments of the present invention, the above R2 is selected from Other variables are as defined in the present invention.

[0088] In some embodiments of the present invention, each R3 is independently selected from H, F, Cl, Br, I, CH3, CH2F, CHF2, CF3 and Other variables are as defined in the present invention.

[0089] In some embodiments of the present invention, each R3 is independently selected from H, CH3 and CHF2, and other variables are as defined in the present invention.

[0090] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.

[0091] In some embodiments of the present invention, the above structural unit Selected from

[0092] In some embodiments of the present invention, the above structural unit Selected from

[0093] In some embodiments of the present invention, the above structural unit Selected from

[0094] In some embodiments of the present invention, the above structural unit Selected from

[0095] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.

[0096] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.

[0097] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.

[0098] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.

[0099] In some embodiments of the present invention, the ring A is selected from phenyl and pyridyl, and the phenyl and pyridyl are independently optionally substituted by 1, 2 or 3 R c Substitution, other variables are as defined in the present invention.

[0100] In some embodiments of the present invention, the ring A is selected from Other variables are as defined in the present invention.

[0101] In some embodiments of the present invention, the compound represented by the above formula (II), its stereoisomers or pharmaceutically acceptable salts thereof are selected from compounds of formula (II-2) or (II-3):

[0102] wherein R2, R3, L and ring A are as defined in the present invention;

[0103] When R3 is not H, the carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.

[0104] In some embodiments of the present invention, the compound of formula (II-2) or (II-3), its stereoisomers or pharmaceutically acceptable salts thereof, wherein R3 is CHF2, and other variables are as defined in the present invention.

[0105] In some embodiments of the present invention, the compound of formula (II-2) or (II-3), its stereoisomer or pharmaceutically acceptable salt thereof is selected from the compound of formula (II-2a) or (II-3a):

[0106] wherein R2, L and ring A are as defined in the present invention.

[0107] In some embodiments of the present invention, the compound of formula (II-3), its stereoisomers or pharmaceutically acceptable salts thereof are selected from:

[0108] in,

[0109] T8 is selected from CH and N;

[0110] L is selected from C 1-4 Alkyl and C 3-6 Cycloalkyl, the C 1-4 Alkyl and C 3-6 The cycloalkyl groups are each independently optionally substituted with 1 or 2 F groups;

[0111] R c selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 Alkyl is optionally substituted with 1, 2 or 3 F;

[0112] R d Selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted with 1, 2 or 3 R;

[0113] Each R is independently selected from H, F, OH, methyl and methoxy;

[0114] The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.

[0115] In some embodiments of the present invention, the compound of formula (III), its stereoisomers or pharmaceutically acceptable salts thereof are selected from:

[0116] Among them, R c 、R d , T8 and L are as defined in the present invention.

[0117] In some embodiments of the present invention, the above compound or a pharmaceutically acceptable salt thereof is selected from:

[0118] in,

[0119] R3 is selected from F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R b replace;

[0120] R1, R2, L2, L3, Ring A and each R b As defined in the present invention.

[0121] In some embodiments of the present invention, the above compound or a pharmaceutically acceptable salt thereof is selected from:

[0122] in,

[0123] R1 is O;

[0124] R2 is C 2-5 Alkynyl, the C 2-5 Alkynyl is optionally substituted with 1, 2 or 3 R d replace;

[0125] R3 is C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R b replace;

[0126] Ring A is selected from phenyl and pyridyl, and the phenyl and pyridyl are each independently optionally substituted by 1, 2 or 3 R c replace;

[0127] The structural unit -L2-L3- is selected from -CH2C(CH3)2-,

[0128] Each R b are independently selected from H, F, Cl, Br, I and OH;

[0129] Each R c are independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;

[0130] Each R d are independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl and C 3-6 Cycloalkyl, the C 1-3 Alkyl and C 3-6 The cycloalkyl groups are each independently optionally substituted with 1, 2 or 3 halogens.

[0131] In some embodiments of the present invention, the compound of formula (P-1) or a pharmaceutically acceptable salt thereof, wherein each Rd are independently selected from H, F, OH, NH2, CH3 and cyclopropyl, and other variables are as defined in formula (P-1) of the present invention.

[0132] In some embodiments of the present invention, the above-mentioned compound (P-1) or a pharmaceutically acceptable salt thereof, wherein R2 is selected from C 2-5 Alkynyl, the C 2-5 Alkynyl is optionally substituted with 1, 2 or 3 R d The other variables are as defined in formula (P-1) of the present invention.

[0133] In some embodiments of the present invention, the compound of formula (P-1) or a pharmaceutically acceptable salt thereof, wherein R3 is selected from CHF2, and the other variables are as defined in formula (P-1) of the present invention.

[0134] In some embodiments of the present invention, the compound of formula (P-1) or a pharmaceutically acceptable salt thereof, wherein the structural unit -L2-L3- is -CH2C(CH3)2-, and the other variables are as defined in formula (P-1) of the present invention.

[0135] The present invention also provides a compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0136] in,

[0137] L1 is selected from CH2 and C(=O);

[0138] L is divided by 2 R a Substituted C 1-3 alkyl;

[0139] R1 is selected from O, S and NR4;

[0140] R2 is selected from C 2-5 Alkenyl and C 2-5 Alkynyl, the C 2-5 Alkenyl and C 2-5 Alkynyl is independently substituted by 1, 2 or 3 R d1 Replace, each R a are independently selected from H, F, Cl, Br, I, OH and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R groups;

[0141] Alternatively, R2 is selected from C 2-5 Alkenyl and C 2-5 Alkynyl, the C 2-5 Alkenyl and C 2-5 Alkynyl is independently substituted by 1, 2 or 3 R d2 Replace, 2 R aThe carbon atom connected to it forms C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl, the C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R;

[0142] Each R3 is independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R b replace;

[0143] R4 is selected from OH, CN and -(OCH2CH2) n -C 1-3 alkoxy;

[0144] n is 0 or 1;

[0145] Ring A is selected from phenyl, 5-6 membered heteroaryl and C 5-6 Cycloalkenyl, the phenyl, 5-6 membered heteroaryl and C 5-6 The cycloalkenyl group is optionally substituted by 1, 2 or 3 R c replace;

[0146] Each R b are independently selected from H, F, Cl, Br, I and OH;

[0147] Each R c are independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;

[0148] Each R d1 are independently selected from F, Cl, Br, I, OH, NH2, -C 3-6 Cycloalkyl-OH and 4-6 membered heterocycloalkyl, the C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted with 1, 2 or 3 R;

[0149] Each R d2 are independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted with 1, 2 or 3 R;

[0150] Each R is independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkoxy, C 1-3 Alkyl and C1-3 Halogenated alkyl.

[0151] The present invention also provides a compound represented by formula (I-1), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0152] in,

[0153] is selected from single bonds and double bonds;

[0154] T1 is selected from C, T2 is selected from N;

[0155] Alternatively, T1 is selected from N, and T2 is selected from C;

[0156] T3 is selected from O, N, NH, C(═O), C(R3)2O, C(R3) and C(R3)2;

[0157] T4 is selected from N, NH, C(═O), C(R3)2O, C(R3) and C(R3)2;

[0158] L1 is selected from CH2 and C(=O);

[0159] L2 and L3 are independently selected from a single bond and -C 1-3 Alkyl-(R a )2;

[0160] R1 is selected from O, S and NR4;

[0161] R2 is selected from OH, NH2, C 1-4 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl and C 3-6 Cycloalkyl, the C 1-4 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl and C 3- 6 cycloalkyl groups are each independently optionally substituted by 1, 2 or 3 R d replace;

[0162] Each R3 is independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R b replace;

[0163] R4 is selected from OH, CN and -(OCH2CH2) n -C 1-3 alkoxy;

[0164] n is 0 or 1;

[0165] Ring A is selected from phenyl, 5-6 membered heteroaryl and C5-6 Cycloalkenyl, the phenyl, 5-6 membered heteroaryl and C 5-6 The cycloalkenyl group is optionally substituted by 1, 2 or 3 R c replace;

[0166] 2 Rs a The carbon atom connected to it forms C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl, the C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R;

[0167] Each R b are independently selected from H, F, Cl, Br, I and OH;

[0168] Each R c are independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;

[0169] Each R d are independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted with 1, 2 or 3 R;

[0170] Each R is independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0171] The present invention also provides a compound represented by formula (I-2), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0172] in,

[0173] is selected from single bonds and double bonds;

[0174] T1 is selected from C, T2 is selected from N;

[0175] Alternatively, T1 is selected from N, and T2 is selected from C;

[0176] T3 is selected from O, N, NH, C(═O), C(R3)2O, C(R3) and C(R3)2;

[0177] T4 is selected from N, NH, C(═O), C(R3)2O, C(R3) and C(R3)2;

[0178] L1 is selected from CH2 and C(=O);

[0179] L2 and L3 are independently selected from a single bond and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R a replace;

[0180] L4 is selected from C 2-5 Alkenyl and C 2-5 Alkynyl;

[0181] R1 is selected from O, S and NR4;

[0182] Each R3 is independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R b replace;

[0183] R4 is selected from OH, CN and -(OCH2CH2) n -C 1-3 alkoxy;

[0184] R5 is selected from F, Cl, Br, I, CN, NH2, OH, -C 3-6 Cycloalkyl-OH and 4-6 membered heterocycloalkyl, the 4-6 membered heterocycloalkyl optionally substituted with 1, 2 or 3 R;

[0185] n is 0 or 1;

[0186] Ring A is selected from phenyl, 5-6 membered heteroaryl and C 5-6 Cycloalkenyl, the phenyl, 5-6 membered heteroaryl and C 5-6 The cycloalkenyl group is optionally substituted by 1, 2 or 3 R c replace;

[0187] Each R a and each R b are independently selected from H, F, Cl, Br, I and OH;

[0188] Each R c are independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;

[0189] Each R is independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkoxy, C 1-3 Alkyl and C1-3 Halogenated alkyl.

[0190] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R is independently selected from H, F, Cl, Br, I, OH, NH2, methoxy, methyl, ethyl, isopropyl, difluoromethyl and trifluoromethyl, and other variables are as defined in the present invention.

[0191] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R is independently selected from H, OH and methyl, and other variables are as defined in the present invention.

[0192] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, two R a The carbon atom to which it is connected forms a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, oxolanyl or pyrrolidinyl group, and the cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, oxolanyl or pyrrolidinyl group is optionally substituted by 1, 2 or 3 R, and other variables are as defined in the present invention.

[0193] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt, the two R a The carbon atom to which it is attached forms a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl or N-methylpyrrolidinyl group, and other variables are as defined in the present invention.

[0194] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R c are independently selected from F, Cl, Br, I and CH3, wherein CH3 is optionally substituted by 1, 2 or 3 halogens, and other variables are as defined herein.

[0195] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R c are independently selected from F, Cl, Br, I, CH3 and CF3, and other variables are as defined in the present invention.

[0196] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each Rc are independently selected from H, F, Cl, Br, I and CH3, wherein CH3 is optionally substituted by 1, 2 or 3 halogens, and other variables are as defined in the present invention.

[0197] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R c are independently selected from H, F, Cl, Br, I, CH3 and CF3, and other variables are as defined in the present invention.

[0198] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R c are independently selected from H and F, and other variables are as defined in the present invention.

[0199] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R d Each of the cyclopropyl, oxetanyl, oxolanyl, azepanyl and oxhexyl groups is independently selected, and the cyclopropyl, oxetanyl, oxolanyl, azepanyl and oxhexyl groups are independently optionally substituted with 1, 2 or 3 R groups, and other variables are as defined in the present invention.

[0200] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R d1 Each of the cyclopropyl-OH, oxetanyl, oxolanyl, azetyl and oxhexyl groups is independently selected from F, Cl, Br, I, OH, NH2, -cyclopropyl-OH, oxetanyl, oxolanyl, azetyl and oxhexyl groups, wherein the cyclopropyl, oxetanyl, oxolanyl, azetyl and oxhexyl groups are independently optionally substituted with 1, 2 or 3 R, and other variables are as defined herein.

[0201] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R d2 Each of the following groups is independently selected from H, F, Cl, Br, I, OH, NH2, methyl, ethyl, isopropyl, cyclopropyl, oxetanyl, oxolanyl, azopentyl and oxhexyl, wherein the methyl, ethyl, isopropyl, cyclopropyl, oxetanyl, oxolanyl, azopentyl and oxhexyl groups are independently optionally substituted with 1, 2 or 3 R, and other variables are as defined herein.

[0202] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R d2 Each of the cyclopropyl, oxetanyl, oxolanyl, azepanyl and oxhexyl groups is independently selected, and the cyclopropyl, oxetanyl, oxolanyl, azepanyl and oxhexyl groups are independently optionally substituted with 1, 2 or 3 R groups, and other variables are as defined in the present invention.

[0203] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the L is selected from Other variables are as defined in the present invention.

[0204] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the L is selected from Other variables are as defined in the present invention.

[0205] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the L1 is selected from CH2, and the other variables are as defined in the present invention.

[0206] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt thereof, the L2 is selected from a single bond, CH2, CH2CH2 and C(CH3)2, and the CH2, CH2CH2 and C(CH3)2 are independently optionally replaced by 1, 2 or 3 R a Substitution, other variables are as defined in the present invention.

[0207] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt, the L2 is selected from a single bond, CH2, CH2CH2, C(CH3)2, Other variables are as defined in the present invention.

[0208] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt, the L3 is selected from a single bond, CH2, CH2CH2 and C(CH3)2, and the CH2, CH2CH2 and C(CH3)2 are independently optionally replaced by 1, 2 or 3 R a Substitution, other variables are as defined in the present invention.

[0209] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt, the L3 is selected from a single bond, CH2, CH2CH2, C(CH3)2, Other variables are as defined in the present invention.

[0210] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit -L2-L3- is selected from -CH2C(CH3)2-, Other variables are as defined in the present invention.

[0211] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt thereof, the L4 is selected from C 2-5 Other variables are as defined in the present invention.

[0212] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the L4 is selected from ethynyl, propynyl, butynyl, pentynyl and isopentenyl, and other variables are as defined in the present invention.

[0213] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is selected from O, NOH, NCN, NOCH3, NOCH2CH3 and NOCH2CH2OCH3, and other variables are as defined in the present invention.

[0214] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is selected from O, and other variables are as defined in the present invention.

[0215] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the R2 is selected from The CH3, Each independently optionally replaced by 1, 2 or 3 R d1 Substitution, other variables are as defined in the present invention.

[0216] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the R2 is selected from The CH3, Each independently optionally substituted by 1, 2 or 3 R d2 Substitution, other variables are as defined in the present invention.

[0217] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the R2 is selected from Other variables are as defined in the present invention.

[0218] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the R2 is selected from Other variables are as defined in the present invention.

[0219] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt, the R2 is selected from OH, NH2, CH3, The CH3, Each independently optionally substituted by 1, 2 or 3 R d Substitution, other variables are as defined in the present invention.

[0220] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt, the R2 is selected from OH, NH2, CH3, Other variables are as defined in the present invention.

[0221] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt, the R2 is selected from OH, NH2, CH3, Other variables are as defined in the present invention.

[0222] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the R2 is selected from Other variables are as defined in the present invention.

[0223] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R3 is independently selected from H, F, Cl, Br, I, CH3, CH2F, CHF2, CF3 and Other variables are as defined in the present invention.

[0224] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, each R3 is independently selected from H, CH3 and CHF2, and other variables are as defined in the present invention.

[0225] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt thereof, the R5 is selected from F, Cl, Br, I, CN, NH2, OH, -cyclopropyl-OH, oxetanyl, oxolanyl, azopentyl and oxhexyl, and the oxetanyl, oxolanyl, azopentyl and oxhexyl are optionally substituted with 1, 2 or 3 Rs, and other variables are as defined herein.

[0226] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, R5 is selected from OH and -cyclopropyl-OH, and other variables are as defined in the present invention.

[0227] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the T3 is selected from -O- and -CH2O-, and the other variables are as defined in the present invention.

[0228] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the T4 is selected from -CH(CHF2)-, and the other variables are as defined in the present invention.

[0229] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0230] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0231] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0232] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0233] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0234] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0235] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit -L-R5 is selected from Other variables are as defined in the present invention.

[0236] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit -L-R5 is selected from Other variables are as defined in the present invention.

[0237] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0238] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0239] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0240] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0241] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0242] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the structural unit Selected from Other variables are as defined in the present invention.

[0243] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomer or pharmaceutically acceptable salt, the ring A is selected from phenyl and pyridyl, and the phenyl and pyridyl are independently optionally substituted by 1, 2 or 3 R c Substitution, other variables are as defined in the present invention.

[0244] In some embodiments of the present invention, in the compound represented by the above formula (I), (I-1) or (I-2), its stereoisomers or pharmaceutically acceptable salts thereof, the ring A is selected from Other variables are as defined in the present invention.

[0245] Some other solutions of the present invention are obtained by any combination of the above variables.

[0246] The present invention provides a compound represented by the following formula, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0247] The present invention also provides a compound represented by the following formula, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0248] The present invention also provides the use of the above-mentioned compound, its stereoisomer or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating ALK inhibitor-related diseases.

[0249] In the above application of the present invention, the ALK inhibitor-related disease is non-small cell lung cancer.

[0250] The present invention also provides the following testing method:

[0251] Test method 1: In vitro kinase inhibition activity test

[0252] Compounds against ALK G1202R / L1196M The kinase inhibitory activity tests of TRKB and TNF-α were completed at Hefei Zhongke Puruisheng Biotechnology Co., Ltd.

[0253] Experimental Materials:

[0254] ALK (G1202R / L1196M) Active was purchased from Carna; SRC Substrate was purchased from SignalChem; IGF1R tide was purchased from SignalChem; ADP-Glo ​​Kinase Assay was purchased from Promega; Kinase assay buffer III was purchased from SignalChem; Nivo multi-label analyzer (PerkinElmer).

[0255] Experimental methods:

[0256] ALK (G1202R / L1196M) kinase inhibition test method:

[0257] Reaction system: ALK (G1202R / L1196M) reaction concentration 8.63 nM, ATP concentration 5.0 μM, substrate IGF1 concentration 0.2 μg / μL, ALK (G1202R / L1196M) kinase buffer is 40 mM Tris-HCl (pH 7.5) + 20 mM magnesium chloride + 0.1 mg / mL BSA + 50 μM DTT.

[0258] Detection method: Add 2 μL kinase and 1 μL compound to a 384 plate; add 2 μL substrate / ATP mixture and incubate at room temperature in the dark for 60 minutes; add 5 μL ADP-Glo TMReagent, incubate at room temperature for 40 minutes; add 10 μL Kinase Detection Reagent, incubate at room temperature for 30 minutes; read the plate on a microplate reader and record the luminescence (set the integration time to 0.5 seconds).

[0259] TRKB kinase inhibition test method:

[0260] Reaction system: TRKB reaction concentration 4.47 nM, ATP concentration 5.0 μM, substrate PolyE4Y1 concentration 0.2 μg / μL, TRKB kinase buffer 40 mM Tris-HCl (pH 7.5) + 20 mM magnesium chloride + 2.5 mM manganese chloride + 0.1 mg / mL BSA + 50 μM DTT.

[0261] The detection method is the same as ALK (G1202R / L1196M).

[0262] Data Analysis:

[0263] The raw data were converted into inhibition rate, IC, using the equation (Sample-Min) / (Max-Min)*100%. 50 The value can be obtained by four-parameter curve fitting (obtained by log(inhibitor) vs.response--Variable slope mode in GraphPad Prism).

[0264] Test method 2: MDR1 test

[0265] Purpose of the experiment:

[0266] The MDCKII-MDR1 monolayer cell assay system was used to evaluate the permeability and efflux ratio of the test compounds to determine the compound's potential to cross the blood-brain barrier and its potential to be effluxed by the P-gp transporter.

[0267] Experimental methods:

[0268] MDCKII-MDR1 cells (from the Netherlands Cancer Institute) were seeded into 96-well cell plates (from Corning) at a cell density of 2.5 × 10 5cells / ml, cultured for 7 days to form a copolymerized cell monolayer. Hank's balanced salt buffer (pH 7.40 ± 0.05) containing 10mM 4-hydroxyethylpiperazineethanesulfonic acid was used as the transport buffer (wherein, the transport buffer of compound 005 was 1% BSA (bovine serum albumin) added to the transport buffer). The bidirectional transport of the test compound at a concentration of 2μM was tested, and the concentration of DMSO in the incubation system was controlled below 1%. After addition of the sample, the cell plate was placed at 37±1°C, 5% CO2 and saturated humidity and incubated for 150 minutes. All samples were quantitatively analyzed by LC-MS / MS method. The apparent permeability coefficient (P app , cm / s), efflux ratio (ER) and recovery rate.

[0269] Apparent permeability coefficient (P app ,cm / s) is calculated using the following formula: P app =(dC r / d t )×V r / (A×C0). Where, dC r / d t is the cumulative concentration of the compound at the receiving end per unit time (μM / s); V r is the volume of the solution at the receiving end (the volume of the solution at the apical and basal ends is 0.075 mL and 0.250 mL, respectively); A is the relative surface area of ​​the cell monolayer (0.0804 cm 2 ); C0 is the starting concentration of the test sample at the dosing end (nM) or the peak area ratio of the reference sample. The efflux ratio is calculated using the following formula: ER = P app (BA) / P app (AB). The recovery rate was calculated using the following formula: % recovery rate = 100 × [(V r ×C r )+(V d ×C d )] / (V d × C0). Where C0 is the starting concentration (nM) of the test sample at the dosing end or the peak area ratio of the reference sample; V d is the volume of the dosing end (0.075 mL on the apical side and 0.250 mL on the basolateral side); C d and C r are the final concentration (nM) of the test sample at the dosing end and the receiving end or the peak area ratio of the reference sample.

[0270] Test Method 3: Antiproliferative Activity Test on Two Ba / F3 Cell Lines: Ba / F3-TEL-NTRK2 and Ba / F3-EML4-ALK-G1202R / L1196M

[0271] Experimental Materials

[0272] (1) Cell line (established by Hefei Zhongke Puruisheng Biopharmaceutical Technology Co., Ltd.)

[0273] ALK G1202R / L1196M Cell line: Ba / F3-EML4-ALK-G1202R / L1196M; TRKB cell line: Ba / F3-TEL-NTRK2.

[0274] (2) Reagents

[0275] RPMI 1640: VivaCell brand, product number C3010-0500; fetal bovine serum: VivaCell brand, product number C04001-500;

[0276] Penicillin-streptomycin solution: Gibco, product number 15140-122; CellTiterGlo: Promega, product number G7573;

[0277] Trypan blue: Solarbio, product number C0040; 96-well white plate: Biosharp, product number BS-MP-96W;

[0278] 96-well plate: Beaver brand, item number 40196.

[0279] (3) Instruments

[0280] Cell counter, manufacturer: Count star, model: IC1000; microplate reader, manufacturer: Molecular Devices, model: SpectraMax Paradigm; carbon dioxide incubator, manufacturer: Thermo, model: HERA cell vios 160i.

[0281] (4) Compound information

[0282] Compounds were prepared in DMSO at a working concentration of 1 mM.

[0283] Experimental methods

[0284] (1) Cell culture: The cell lines were cultured in an incubator at 37°C and 5% CO2. Cells were passaged regularly and cells in the logarithmic growth phase were used for plating.

[0285] (2) Compound storage plate preparation: Prepare the test compound into a 10 mM solution (Stock Con.) with DMSO; then prepare the compound into a 1 mM solution (Work Con.) with DMSO; take 1 μL of Stock solution and 9 μL of DMSO to prepare 10 μL of Work solution;

[0286] (3) Prepare 1000× compound storage plates (tubes): dilute the compound three-fold with DMSO from 1 μM to the lowest concentration, for a total of 8 concentrations;

[0287] (4) Preparation of 20× compound working solution: Add 98 μL of cell culture medium to a flat-bottomed 96-well transparent plate. Pipette 2 μL of compound from a 1000× compound storage plate and add it to the cell culture medium in the 96-well transparent plate. Add 2 μL of DMSO to the vehicle control. After adding the compound or DMSO, mix thoroughly by pipetting with a dispenser.

[0288] (5) Stain the cells with trypan blue and count the living cells. The cell viability is required to be above 90%, and the cell concentration is adjusted to an appropriate concentration.

[0289] (6) Add 95 μL of cell suspension (2000 cells / well) to each well of the compound test cell plate, and add culture medium without cells (containing 0.1% DMSO) to the Min control wells;

[0290] (7) Compound assay cell plate dosing: 5 μL of 20× compound working solution was added to the cell culture plate. 5 μL of DMSO-cell culture medium mixture was added to the Max control, with a final DMSO concentration of 0.1%;

[0291] (8) Incubate the culture plate in a 37°C, 5% CO 2 incubator for 72 hours;

[0292] (9) Follow the instructions of the Promega CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega-G7573) to perform the following operations: melt the CellTiter-Glo buffer and bring it to room temperature; bring the CellTiter-Glo substrate to room temperature; add CellTiter-Glo buffer to a bottle of CellTiter-Glo substrate to dissolve the substrate, thereby preparing the CellTiter-Glo working solution; slowly vortex to fully dissolve; remove the cell culture plate and let it stand for 10 minutes to equilibrate to room temperature; add 50 μL (equal to half the volume of the cell culture solution in each well) of CellTiter-Glo working solution to each well; shake the culture plate on an orbital shaker for 2 minutes to induce cell lysis; let the culture plate stand at room temperature for 10 minutes to stabilize the luminescent signal; detect the luminescent signal on a SpectraMax Paradigm plate reader; and perform the CellTiter-Glo luminescent cell viability assay.

[0293] Data Analysis

[0294] The SpectraMax Paradigm readings were used to obtain the corresponding fluorescence value RLU per well; the cell proliferation inhibition rate (Inhibition Rate) data were calculated using the formula Inhibition Rate (Inh%) = 100-(RLU Drug -RLU Min ) / (RLU Max -RLU Min )*100%. The inhibition rates corresponding to different concentrations of compounds were calculated in Excel, and then the inhibition rate curve was plotted using GraphPad Prism software and related parameters were calculated, including the maximum and minimum inhibition rates of cells, IC 50 value.

[0295] Technical Effects

[0296] The compounds of the present invention have significant inhibitory activity against ALK kinase mutants, while their inhibition against TRKB kinase is relatively weak, showing good selectivity. The anti-proliferative activity test results of the Ba / F3 cell line also show that the compounds of the present invention have potent inhibitory activity against both Ba / F3-EML4-ALK cells and ALK mutant cells, while their inhibition against Ba / F3-TEL-NTRK2 cells is relatively weak, showing excellent selectivity. Therefore, the high selectivity of the compounds of the present invention can avoid or reduce central nervous system toxicity caused by TRKB inhibition.

[0297] At the same time, the compounds of the present invention are hypertonic, low-efflux compounds, exhibit good metabolic stability in liver microsomes of various species, have weak inhibitory activity on CYP2C9, have no CYP3A4 induction activity, and have a low risk of drug interactions; the compounds of the present invention have excellent pharmacokinetic properties in various species; in vivo efficacy experiments show that the compounds of the present invention also have significant tumor inhibition effects and exhibit good in vivo efficacy.

[0298] Definition and Description

[0299] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be construed as indefinite or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.

[0300] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0301] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, which are prepared by reacting the compounds of the present invention with relatively nontoxic acids or bases, having specific substituents. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the compounds with a sufficient amount of base in neat solution or a suitable inert solvent. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the compounds with a sufficient amount of acid in neat solution or a suitable inert solvent. Certain specific compounds of the present invention contain both basic and acidic functional groups and can be converted into either base or acid addition salts.

[0302] Pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of a suitable base or acid in water or an organic solvent or a mixture of the two.

[0303] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are encompassed within the scope of the present invention.

[0304] Unless otherwise indicated, the term "enantiomer" or "optical isomer" refers to stereoisomers that are mirror images of one another.

[0305] Unless otherwise indicated, the term "cis-trans isomers" or "geometric isomers" arises from the inability to rotate freely about double bonds or single bonds forming ring carbon atoms.

[0306] Unless otherwise indicated, the term "diastereomer" refers to stereoisomers that have two or more chiral centers and that are not mirror images of each other.

[0307] Unless otherwise specified, use a solid wedge key. and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond and straight dashed key Indicate the relative configuration of stereocenters with a wavy line Indicates a wedge-shaped solid key and / or dotted wedge key Or use a wavy line Indicates a straight solid bond and / or straight dashed key

[0308] Unless otherwise specified, when a compound contains a double bond structure, such as a carbon-carbon double bond, a carbon-nitrogen double bond, and a nitrogen-nitrogen double bond, and each atom on the double bond is connected to two different substituents (in a double bond containing a nitrogen atom, a lone pair of electrons on the nitrogen atom is regarded as a substituent to which it is connected), if the atoms on the double bond in the compound and their substituents are separated by a denoted by , it represents the (Z) isomer, (E) isomer or a mixture of both isomers of the compound.

[0309] Unless otherwise indicated, the terms "enriched in one isomer", "isomerically enriched", "enriched in one enantiomer" or "enantiomerically enriched" mean that the content of one isomer or enantiomer is less than 100%, and the content of that isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.

[0310] Unless otherwise indicated, the term "isomer excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomeric excess (ee value) is 80%.

[0311] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are resolved by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is typically accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., carbamate formation from an amine).

[0312] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C). For example, deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged drug biological half-life. All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of this invention.

[0313] The terms "optional" or "optionally" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0314] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., =O), it means that two hydrogen atoms are replaced. When the substituent is =CH2, it means that two hydrogen atoms are replaced.

[0315] The term "optionally substituted" means that the group may be substituted or not substituted, and unless otherwise specified, the type and number of the substituents may be any based on chemical feasibility.

[0316] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, with each occurrence of R being an independent choice. Furthermore, combinations of substituents and / or their variants are permissible only if such combinations result in stable compounds.

[0317] When the number of a linking group is 0, such as -(CRR)0-, it means that the linking group is a single bond.

[0318] When the number of a substituent is 0, it means that the substituent does not exist, for example, -A-(R)0 means that the structure is actually -A.

[0319] When a substituent is vacant, it means that the substituent does not exist. For example, when X in AX is vacant, it means that the structure is actually A.

[0320] When one of the variables is selected from a single bond, it means that the two groups it connects are directly connected. For example, when L in ALZ represents a single bond, it means that the structure is actually AZ.

[0321] When the substituents listed do not specify through which atom they are connected to the substituted group, such substituents can be bonded through any atom thereof. For example, a pyridyl substituent can be connected to the substituted group through any carbon atom on the pyridine ring.

[0322] When the linking group is listed without specifying its linking direction, its linking direction is arbitrary, for example, The connecting group L is -MW-, in which case -MW- can connect ring A and ring B in the same direction as the reading order from left to right to form You can also connect ring A and ring B in the opposite direction of reading from left to right to form Combinations of linkers, substituents, and / or variations thereof are permissible only if such combinations result in stable compounds.

[0323] Unless otherwise specified, when a group has one or more connectable sites, any one or more sites of the group can be connected to other groups through chemical bonds. When the chemical bond connection mode is non-positional and there are H atoms at the connectable sites, when the chemical bond is connected, the number of H atoms at the site will decrease accordingly with the number of connected chemical bonds, and become a group with a corresponding valence. The chemical bond connecting the site to other groups can be a straight solid bond. Straight dotted key or wavy lines For example, the straight solid bond in -OCH3 indicates that it is connected to other groups through the oxygen atom in the group; The straight dashed bond in the group indicates that the two ends of the nitrogen atom in the group are connected to other groups; The wavy line in the phenyl group indicates that it is connected to other groups through the carbon atoms at positions 1 and 2 in the phenyl group; Indicates that any linkable site on the piperidinyl group can be connected to other groups through a chemical bond, including at least In these four connection methods, even if an H atom is drawn on -N-, Still includes For groups connected in this way, when one chemical bond is connected, the H at that site will be reduced by one and become a corresponding monovalent piperidine group.

[0324] Unless otherwise specified, the number of atoms in a ring is generally defined as the number of members of the ring, for example, a "5-7 membered ring" refers to a "ring" having 5-7 atoms arranged around it.

[0325]

[0046] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.

[0326] Unless otherwise specified, the term “C 1-4 "Alkyl" by itself or in combination with other terms refers to a straight or branched chain saturated hydrocarbon group consisting of 1 to 4 carbon atoms. 1-4 "Alkyl" is used to represent a straight or branched chain saturated hydrocarbon group consisting of 1 to 4 carbon atoms. 1-4 Alkyl groups include C4, C3, C1-3 、C 1-2 and C 2-3 Alkyl, etc.; it may be monovalent, divalent or polyvalent. 1-4 Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.

[0327] Unless otherwise specified, the term “C 1-3 "Alkyl" by itself or in combination with other terms refers to a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms. 1-3 "Alkyl" is used to represent a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms. 1-3 Alkyl groups include C3, C 1-2 and C 2-3 Alkyl, etc.; it may be monovalent, divalent or polyvalent. 1-3 Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.

[0328] Unless otherwise specified, the term “C 1-3 "Haloalkyl" means monohaloalkyl and polyhaloalkyl containing 1 to 3 carbon atoms. 1-3 Haloalkyl groups include C 1-2 、C 2-3 , C3, C2 and C1 haloalkyl, etc. 1-3 Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, pentachloroethyl, 3-bromopropyl, and the like.

[0329] Unless otherwise specified, “C 2-5 "Alkenyl" by itself or in combination with other terms refers to a straight or branched hydrocarbon group consisting of 2 to 5 carbon atoms containing at least one carbon-carbon double bond, which can be located at any position of the group. 2-5 Alkenyl groups include C 2-4 、C 2-3 , C5, C4, C3 and C2 alkenyl, etc.; which may be monovalent, divalent or polyvalent. 2-5 Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, butadienyl, piperyl, and the like.

[0330] Unless otherwise specified, “C 2-5 "Alkynyl" by itself or in combination with other terms refers to a straight or branched hydrocarbon group consisting of 2 to 5 carbon atoms containing at least one carbon-carbon triple bond, which may be located at any position of the group. 2-5 Alkynyl groups include C 2-4、C 2-3 , C5, C4, C3 and C2 alkynyl, etc. It can be monovalent, divalent or polyvalent. 2-5 Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and the like.

[0331] Unless otherwise specified, the term “C 1-3 "Alkoxy" by itself or in combination with other terms refers to those alkyl groups containing 1 to 3 carbon atoms that are attached to the rest of the molecule through an oxygen atom. It can be monovalent, divalent or polyvalent. The C 1-3 Alkoxy groups include C 1- 2. C 2-3 , C3 and C2 alkoxy, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.

[0332] Unless otherwise specified, the term “C 1-4 "Alkylamino" by itself or in combination with other terms refers to those alkyl groups containing 1 to 4 carbon atoms that are attached to the rest of the molecule through a nitrogen atom. It can be monovalent, divalent or polyvalent. The C 1-4 Alkylamino groups include C 1- 3. C 2-3 , C4, C3 and C2 alkylamino, etc. 1-4 Examples of alkylamino groups include, but are not limited to, -NHCH3, -NHCH2CH3, -N(CH3)2, and the like.

[0333] Unless otherwise specified, the term “C 1-3 "Alkylamino" by itself or in combination with other terms refers to those alkyl groups containing 1 to 3 carbon atoms that are attached to the rest of the molecule through a nitrogen atom. It can be monovalent, divalent or polyvalent. The C 1-3 Alkylamino groups include C 1- 2. C 2-3 , C3 and C2 alkylamino, etc. 1-3 Examples of alkylamino groups include, but are not limited to, -NHCH3, -NHCH2CH3, -N(CH3)2, and the like.

[0334] Unless otherwise specified, “C 3-6 "Cycloalkyl" by itself or in combination with other terms refers to a saturated monocyclic hydrocarbon group consisting of 3 to 6 carbon atoms. 3-6 Cycloalkyl groups include C 3-5 、C 4-5 and C 5-6 Cycloalkyl, etc.; it may be monovalent, divalent or polyvalent. 3-6Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0335] Unless otherwise specified, “C 5-6 "Cycloalkenyl" by itself or in combination with other terms refers to a partially unsaturated monocyclic hydrocarbon group consisting of 5 to 6 carbon atoms containing at least one carbon-carbon double bond. 5-6 The cycloalkenyl group includes C5 or C6 cycloalkenyl groups, etc.; it may be monovalent, divalent or polyvalent. 5-6 Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.

[0336] Unless otherwise specified, the term "4-6 membered heterocycloalkyl" by itself or in combination with other terms refers to a saturated monocyclic group consisting of 4 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the carbon atoms are optionally oxoed (i.e., C(O)), the nitrogen atoms are optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)). p , p is 1 or 2). In addition, with respect to the "4-6 membered heterocycloalkyl", a heteroatom may occupy the position at which the heterocycloalkyl is attached to the rest of the molecule. The 4-6 membered heterocycloalkyl includes 5-6 membered, 4 membered, 5 membered, and 6 membered heterocycloalkyls. It may be monovalent, divalent, or multivalent. Examples of 4-6 membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl or hexahydropyridazinyl, etc.

[0337] Unless otherwise specified, the terms "5-6 membered heteroaromatic ring" and "5-6 membered heteroaryl" are used interchangeably in the present invention. The term "5-6 membered heteroaryl" refers to a monocyclic group with a conjugated π electron system consisting of 5 to 6 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p, p is 1 or 2). 5-6 membered heteroaryl can be connected to the rest of the molecule through a heteroatom or a carbon atom. The 5-6 membered heteroaryl includes 5-membered and 6-membered heteroaryl. Examples of the 5-6 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl) and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl, etc.), furyl (including 2-furyl and 3-furyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl, etc.), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, etc.).

[0338] Unless otherwise specified, the term "aromatic ring" refers to a cyclic group with a conjugated π electron system, where the atoms are covered by a delocalized π electron cloud. In the structural formula, when the atomic valence and covalent bonding rules are met, it can be written in the form of alternating single and double bonds, or in the form of Represents a delocalized π electron cloud. For example, the structural formula The structures represented are the same; the structural formula The structures represented are all the same. They can be monocyclic or fused polycyclic ring systems, wherein each ring is aromatic. Unless otherwise specified, the ring optionally contains 0, 1 or more heteroatoms independently selected from O, S and N.

[0339] The structures of the compounds of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compounds, the absolute configuration can be confirmed by conventional techniques in the art. For example, single crystal X-ray diffraction (SXRD) is used to collect diffraction intensity data on the cultured single crystal using a Bruker D8 venture diffractometer, using CuKα radiation as the light source and scanning mode: After scanning and collecting relevant data, the crystal structure is further analyzed using the direct method (Shelxs97) to confirm the absolute configuration.

[0340] The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present invention.

[0341] The present invention uses the following abbreviations: aq represents water; DCM represents dichloromethane; PE represents petroleum ether; DMSO represents dimethyl sulfoxide; EA and EtOAc both represent ethyl acetate; EtOH represents ethanol; MeOH represents methanol; ACN represents acetonitrile; DMF represents N,N-dimethylformamide; Tf represents trifluoromethanesulfonyl; TBS represents tert-butyldimethylsilyl; PMB represents p-methoxybenzyl; TMS represents trimethylsilyl; THP represents tetrahydropyranyl; and LiBH4 represents lithium borohydride.

[0342] The solvents used in the present invention can be obtained commercially. Software naming, commercially available compounds use supplier catalog names. DETAILED DESCRIPTION

[0343] The present invention is described in detail below by examples, but it is not intended to limit the present invention in any way. The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement modes well known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present invention. It will be apparent to those skilled in the art that various changes and modifications will be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.

[0344] Reference Example 1: Compound B-1

[0345] Step 1:

[0346] Dissolve B-1-1 (90 g, 343.12 mmol) in dichloromethane (700 mL). Add sodium periodate (169.8 g, 793.86 mmol) and 6 mL of saturated sodium bicarbonate solution sequentially at 24°C. After 5 minutes, add sodium bicarbonate (12 g, 142.85 mmol). After stirring at room temperature for 2 hours, add magnesium sulfate (180 g, 1.50 mol). Filter the reaction mixture, wash the filter cake with dichloromethane (2 x 180 mL), and collect the filtrate to obtain a crude dichloromethane solution of B-1-2, which is used directly in the next step.

[0347] Step 2:

[0348] The crude dichloromethane solution of B-1-2 obtained in step 1 was added dropwise with diethylaminosulfur trifluoride (686.18 mmol, 90.66 mL) at 24 ° C and stirred at 20 ° C for 14 hours. The resulting reaction solution was poured into a sodium bicarbonate solution dissolved in crushed ice in small amounts several times to quench. The liquid was separated, and the organic phase was washed with water (1000 mL) and saturated brine (500 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filter residue was rinsed with dichloromethane (150 mL). The filtrate was concentrated under reduced pressure to obtain compound B-1-3. 1 H NMR (400MHz, CDCl3): δppm 5.88-5.55(m,1H), 4.25-4.22(m,1H), 4.16-4.11(m,1H), 4.10-4.06(m,1H), 1.47(s,3H), 1.39(s,3H).

[0349] Step 3:

[0350] Dissolve B-1-3 (22 g, 144.60 mmol) in acetonitrile (190 mL) and H2O (10 mL), add bis(acetonitrile)palladium(II) chloride (750.30 mg, 2.89 mmol), and stir at 60°C under N2 atmosphere for 5 hours. After cooling to room temperature, filter the reaction mixture, and concentrate the filtrate under reduced pressure to obtain crude B-1-4.

[0351] Step 4:

[0352] The crude product B-1-4 (22 g) was dissolved in dichloromethane (400 mL), and imidazole (11.81 g, 173.53 mmol) and tert-butyldimethylsilyl chloride (23.97 g, 159.07 mmol) were added sequentially at 0 ° C. The mixture was heated to room temperature and stirred for 2 hours. The reaction solution was diluted with dichloromethane (600 mL) and washed with 400 mL of water. The resulting organic phase was washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:0-10:1) to obtain compound B-1-5. 1 H NMR (400MHz, DMSO-d6): δppm 5.99-5.67 (m, 1H), 5.57 (d, J = 5.6Hz, 1H), 3.74-3.53 (m, 3H), 0.84 (s, 9H), 0.02 (s, 6H).

[0353] Step 5:

[0354] Dissolve B-1-5 (26.2 g, 115.76 mmol) in dichloromethane (400 mL), add pyridine (185.21 mmol, 14.95 mL) and trifluoromethanesulfonic anhydride (138.91 mmol, 22.92 mL) in sequence at -30°C to -20°C, and stir at 0°C for 2 hours. The reaction solution was diluted with dichloromethane (400 mL) and washed with 300 mL of water. The resulting organic phase was washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:0-10:1) to obtain compound B-1-6. 1 H NMR (400MHz, CDCl3): δppm 6.20-5.85(m,1H), 4.93-4.82(m,1H), 4.03-3.97(m,2H), 0.91(s,9H), 0.11(s,6H).

[0355] Step 6:

[0356] Dissolve B-1-6 (28.94 g, 80.75 mmol) in 1,4-dioxane (250 mL), add 4-methoxybenzylamine (96.90 mmol, 12.54 mL) and triethylamine (96.90 mmol, 13.49 mL) in sequence, and stir at 90°C for 8 hours. After the reaction solution cools to room temperature, add water (300 mL) to the reaction solution, extract with ethyl acetate (400 mL*2), combine the organic phases, wash with saturated brine (300 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate to obtain the crude product. The crude product is separated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0-10:1) to obtain compound B-1-7. 1 HNMR (400MHz, CDCl3): δppm 7.22-7.20(m,2H),6.86-6.81(m,2H),5.90-5.58(m,1H),3.87-3.75(m,2H), 3.75(s,3H),3.68-3.64(m,2H),2.89-2.84(m,1H),0.83(s,9H),0.02(s,6H).

[0357] Step 7:

[0358] Dissolve B-1-7 (26.99 g, 78.12 mmol) in tetrahydrofuran (280 mL), then add tetrabutylammonium fluoride in tetrahydrofuran (1 M, 78.12 mL) and stir at 24°C for 2 hours. The reaction mixture is diluted with ethyl acetate (500 mL x 3) and washed with 300 mL of water. The resulting organic phase is washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain the crude product. B-1 is then isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 0:1) to obtain B-1. 1 H NMR (400MHz, CDCl3): δppm 7.20-7.16(m,2H),6.86-6.75(m,2H),5.95-5.56(m,1H),3.85-3.75(m,2 H),3.73(s,3H),3.71-3.63(m,1H),3.56-3.49(m,1H),2.98-2.85(m,1H).

[0359] Reference Example 2: Compound B-2

[0360] Step 1:

[0361] B-2-1 (5.0 g, 32.23 mmol) was dissolved in ethyl acetate (50 mL), and potassium carbonate (0.23 g, 1.61 mmol) was added. The mixture was cooled to -5 °C under a nitrogen atmosphere, and N-bromosuccinimide (7.17 g, 40.28 mmol) was added. The temperature was then gradually raised to 20 °C and stirred for 2 hours. The reaction solution was washed with 50 mL of saturated sodium sulfite solution, extracted with ethyl acetate (2*50 mL), and the organic phases were combined and washed with saturated brine (2*50 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (mobile phase PE:EA = 1:0 to 1:1) to obtain B-2-2. 1 H NMR (400MHz, DMSO-d6) δppm 1.26 (t, J = 7.03Hz, 3H), 4.18 (q, J = 7.11Hz, 2H), 6.26 (s, 2H), 12.15 (s, 1H); LCMS: m / z = 233.7, 235.7 [M+H] + .

[0362] Step 2:

[0363] Dissolve B-2-2 (86.0 g, 367.4 mmol), diethyl 2-fluoromalonate (98.2 g, 551.2 mmol), and sodium ethoxide (62.5 g, 918.6 mmol) in ethanol (1000 mL). Heat to 78°C and stir for 6 hours. After cooling to room temperature, concentrate under reduced pressure to remove ethanol. Add 1 M hydrochloric acid solution dropwise to adjust the pH to approximately 3. Stir at 25°C for 1 hour, filter, and dry the filter cake to obtain B-2-3. 1 H NMR (400MHz, DMSO-d6) δppm 1.27 (t, J = 7.03Hz, 3H), 4.25 (q, J = 7.11Hz, 2H), 7.84 (s, 1H), 9.63 (br s, 1H); LCMS: m / z = 319.7, 321.7 [M+H] + .

[0364] Step 3:

[0365] B-2-3 (43.0 g, 134.3 mmol) was dissolved in phosphorus oxychloride (454.8 mL, 4.89 mol). N,N-diisopropylamine (32.2 mL, 201.5 mmol) was added dropwise at 0°C. The temperature was gradually raised to 100°C and stirred for 3 hours. After the reaction solution was cooled to room temperature, most of the phosphorus oxychloride was recovered by distillation under reduced pressure. The resulting solution was slowly added to water (450 mL) to quench the precipitated solid. The solid was filtered and the filter cake was washed with water (3*50 mL). The filtrate was neutralized and discarded. The resulting filter cake was redissolved in methyl tert-butyl ether (200 mL), stirred at 25°C for 0.5 hours, filtered, and the filter cake was collected to obtain B-2-4. LCMS: m / z = 377.7, 379.7 [M+Na] + .

[0366] Step 4:

[0367] B-2-4 (1.9 g, 5.32 mmol) was dissolved in ethanol (45 mL), tetrahydrofuran (45 mL), and water (30 mL). Ammonium chloride (1.54 g, 28.77 mmol) was then added. Zinc powder (1.39 g, 21.21 mmol) was added portionwise at 0°C. The reaction mixture was stirred at 0°C for 0.5 hours. The reaction mixture was filtered, and the filtrate was extracted with dichloromethane (2 x 30 mL), washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure to obtain the crude product, which was then separated and purified by column chromatography (mobile phase: PE:EA = 1:0 to 3:1) to obtain B-2. LCMS: m / z = 321.9, 323.9 [M+H] + .

[0368] Reference Example 3: Compound B-3

[0369] Step 1:

[0370] Dissolve thionyl chloride (74.44 mmol, 5.4 mL) in acetonitrile (35 mL). Slowly add B-3-1 (5.0 g, 26.42 mmol) dissolved in acetonitrile (25 mL) dropwise at -40°C. Stir thoroughly, then add pyridine (142.48 mmol, 11.5 mL). Stir at 15°C for 2 hours. Add 150.0 mL of ethyl acetate to the reaction solution, filter, and concentrate the filtrate under reduced pressure. The resulting crude product is separated and purified by column chromatography (PE:EA = 1:1) to obtain compound B-3-2. 1 H NMR (400MHz, CDCl3): δppm 4.77–4.56 (m, 1H), 4.35–4.33 (m, 1H), 1.52 (s, 6H), 1.46 (s, 9H); LCMS: m / z=258.1[M+Na] + .

[0371] Step 2:

[0372] B-3-2 (1.0 g, 4.25 mmol) and ruthenium trichloride hydrate (4.4 mg, 19.7 μmol) were dissolved in acetonitrile (10.5 mL) under a nitrogen atmosphere. Sodium periodate (5.3 g, 24.8 mmol) dissolved in 10.5 mL of water was added at 0°C, and then the temperature was raised to room temperature (approximately 20°C) and stirred for 16 hours. The reaction solution was diluted with 100 mL of water and extracted with dichloromethane (100 mL*3). The resulting organic phase was washed with 100 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by column chromatography (PE:EA=1:1) to obtain B-3. 1 H NMR (400MHz, CDCl3): δppm 4.23 (s, 2H), 1.59 (s, 9H), 1.56 (s, 6H); LCMS: m / z=252.1[M+1] + .

[0373] Reference Example 4: Compound B-4

[0374] Step 1:

[0375] Dissolve B-4-1 (0.5 g, 14.03 mmol) and B-3 (0.74 g, 2.94 mmol) in DMF (10.0 mL), then add potassium carbonate (1.02 g, 7.35 mmol). Heat to 50°C and stir for 4 hours. Add 5 mL of dichloromethane to dilute the reaction solution, filter, and concentrate the filtrate under reduced pressure to obtain the crude product. The crude product is isolated and purified by column chromatography (PE:EA = 10:1) to obtain B-4-2. 1H NMR (400MHz, CDCl3): δppm 7.49-7.44(m,1H),7.12-7.04(m,1H),6.89-6.84(m,1H),3.91(s,2H),3.84(s,3H),1.36(s,6H),1.33(s,9H); LCMS: m / z=364.1[M+Na] + .

[0376] Step 2:

[0377] B-4-2 (0.3 g, 0.88 mmol) was dissolved in tetrahydrofuran (4.0 mL). LiBH4 (38.3 mg, 1.76 mmol) was added at 0°C and stirred at room temperature for 18 hours. The reaction was quenched with 5.0 mL of water, followed by the addition of 1 mL of 2M sodium hydroxide solution. The mixture was extracted with dichloromethane (10 mL x 3). The resulting organic phase was washed with 5.0 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was isolated and purified by column chromatography (PE:EA = 10:1) to obtain B-4-3. 1 H NMR (400MHz, CDCl3): δppm 7.09-7.05(m,1H),6.97-6.90(m,1H),6.86-6.79(m,1H),4.73-4.71(m,1H),4. 71-4.67(m,2H),4.03(s,2H),1.43(s,6H),1.41(s,9H); LCMS: m / z=336.1[M+Na] + .

[0378] Step 3:

[0379] B-4-3 (0.1 g, 0.32 mmol) was dissolved in dichloromethane (3.0 mL), and N,N-diisopropylethylamine (0.96 mmol, 167 μL) was added. Methanesulfonyl chloride (0.41 mmol, 32.0 μL) was then added at 0°C. The mixture was then warmed to 25°C and stirred for 18 hours. The reaction was quenched by the addition of 3 mL of 2M hydrochloric acid solution at 0°C, diluted with 15 mL of water, and extracted with dichloromethane (15 mL x 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was isolated and purified by column chromatography (PE:EA = 10:1) to obtain B-4. 1H NMR (400MHz, CDCl3): δppm 7.03-6.98(m,1H),6.93-6.86(m,1H),6.79-6.72(m,1H),4.53(s,2H),3.96(s,2H),1.37(s,6H),1.33(s,9H); LCMS:m / z=354.0[M+Na] + .

[0380] Reference Example 5: Compound B-5

[0381] Step 1:

[0382] B-5-1 (5 g, 32.23 mmol) and pyridine hydrochloride (14.90 g, 128.93 mmol) were added to a round-bottom flask and heated to 145°C for 1 hour. After the reaction solution cooled to room temperature, water (200 mL) was added to the reaction solution, and then extracted with EA (500 mL*2). The resulting organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain B-5-2. 1 H NMR (400MHz, CDCl3) δppm10.20(s,1H),7.93-8.02(m,1H),7.83-7.87(m,1H).

[0383] Step 2:

[0384] B-5-2 (3.0 g, 21.26 mmol) was dissolved in DMF (30 mL), followed by the addition of B-3 (4.86 g, 19.33 mmol) and potassium carbonate (6.68 g, 48.32 mmol). The mixture was heated to 50°C and stirred for 14 hours. The mixture was filtered, the filter cake was rinsed with EA (20 mL), and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by column chromatography (PE:EA = 10:1 to 4:1) to obtain B-5-3. LCMS: m / z = 213.1 [M+1-100] + .

[0385] Step 3:

[0386] B-5-3 (1.9 g, 6.08 mmol) was dissolved in EtOH (20 mL). Sodium borohydride (1.15 g, 30.42 mmol) was added under a nitrogen atmosphere at 0°C and the mixture was allowed to react at 25°C for 3 hours. Water (10 mL) was added to the reaction mixture at 0°C and stirred for 0.5 hours. After complete quenching, the mixture was extracted with EA (200 mL*2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by column chromatography (PE:EA = 10:1 to 5:1) to obtain B-5-4. 1H NMR (400MHz, CDCl3) δppm 7.95(d,J=3.01Hz,1H),7.57(dd,J=8.78,3.01Hz,1H),6.62(brs,1H),5.37(t,J=5.52Hz, 1H),4.48(d,J=5.52Hz,2H),4.25(s,2H),1.33(s,9H),1.25(s,6H); LCMS: m / z=315.1[M+1] + .

[0387] Step 4:

[0388] B-5-4 (1 g, 3.18 mmol) was dissolved in DCM (20 mL), followed by the addition of N,N-diisopropylethylamine (9.54 mmol, 1.66 mL). The mixture was cooled to 0°C under a nitrogen atmosphere, and then methylsulfonyl chloride (6.81 mmol, 527.03 μL) was slowly added dropwise. The mixture was allowed to react at 0°C for 1 hour, and then the temperature was raised to 25°C for 2 hours. The reaction solution was slowly added dropwise to an ice-cold saturated sodium bicarbonate solution (50 mL) and extracted with DCM (200 mL x 2). The resulting organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by column chromatography (PE:EA = 10:1 to 5:1) to obtain B-5. 1 H NMR (400MHz, CDCl3) δppm 7.89–7.96(m,1H),7.45-7.48(m,1H),4.60(s,2H),4.35(s,2H),1.41(s,15H).

[0389] Reference Example 6: Compound B-6

[0390] Step 1:

[0391] Dissolve B-6-1 (1 g, 6.45 mmol) in methanol (10 mL), then add sodium cyanoborohydride (810.20 mg, 12.89 mmol) and stir at 25°C for 1.5 hours. Add additional sodium cyanoborohydride (607.65 mg, 9.67 mmol) and stir for 1 hour. Dilute the reaction solution with saturated sodium chloride (20 mL) and extract with ethyl acetate (20 mL*3). The resulting organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain the crude product. The crude product is purified by column chromatography (PE:EA = 1:0 to 3:1) to obtain B-6-2. 1H NMR (400MHz, CDCl3) δ7.92 (d, J = 2.9 Hz, 1H), 7.44 (dd, J = 3.0, 8.0 Hz, 1H), 4.65 (s, 2H), 3.97 (s, 3H), 2.18 (brd, J = 2.5 Hz, 1H).

[0392] Step 2:

[0393] Dissolve B-6-2 (0.9 g, 5.73 mmol) in dichloromethane (9 mL). Cool to 0°C, then slowly add thionyl chloride (0.83 mL, 11.45 mmol) dropwise. Warm to 20°C and stir for 1 hour. The resulting reaction solution is concentrated under reduced pressure to obtain crude B-6. Use it directly in the next reaction without purification. 1 H NMR (400MHz, CDCl3) δ7.97 (d, J = 2.9 Hz, 1H), 7.50 (dd, J = 2.9, 7.9 Hz, 1H), 4.57 (s, 2H), 3.98 (s, 3H).

[0394] Reference Example 7: Compound B-7

[0395] Step 1:

[0396] B-7-1 (5 g, 26.70 mmol), pyridine (8.62 mL, 106.82 mmol), and 4-dimethylaminopyridine (652.48 mg, 5.34 mmol) were dissolved in dichloromethane (100 mL). p-Toluenesulfonyl chloride (5.60 g, 29.37 mmol) was then added and stirred at 25°C for 16 hours. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (50 mL x 2). The resulting organic phase was washed sequentially with 20% aqueous citric acid (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:0 to 3:1) to obtain B-7-2. 1 H NMR (400MHz, CDCl3) δ7.77(d,J=8.3Hz,2H),7.34(d,J=8.1Hz,2H),4.98(brs,1H),4 .65(brs,1H),4.22-4.08(m,1H),2.55-2.42(m,5H),2.33-2.19(m,2H),1.42(s,9H).

[0397] Step 2:

[0398] Dissolve B-7-2 (2 g, 5.86 mmol) and ethyl acetate hydrochloride (4 M, 10.0 mL) in ethyl acetate (10 mL) and stir at 25°C for 3 hours. The reaction mixture is concentrated under reduced pressure to obtain the hydrochloride salt of B-7. 1 H NMR (400MHz, CDCl3) δ7.84-7.76(m,2H),7.46(d,J=8.6Hz,2H),5.08(tt,J=5.0,7.3Hz,1H),3.93-3.84(m,1H),2.68-2.56(m,2H),2.53-2.43(m,5H).

[0399] Reference Example 8: Compound B-8

[0400] Step 1:

[0401] Dissolve B-8-1 (5 g, 28.68 mmol) in methanol (30 mL), then add concentrated hydrochloric acid (12 M, 45.6 μL) and stir at 25°C for 12 hours. The resulting reaction mixture is concentrated under reduced pressure at 25-30°C to obtain B-8-2. 1 H NMR (400MHz, CDCl3) δ3.76 (q, J = 7.2Hz, 2H), 1.22 (t, J = 7.2Hz, 3H), 0.95–0.94 (m, 4H).

[0402] Step 2:

[0403] Methylmagnesium bromide (3.0M in tetrahydrofuran, 8.67 mL) was added to tetrahydrofuran (12 mL) at 0°C, followed by the slow addition of a solution of B-8-2 (2.06 g, 20.17 mmol) in tetrahydrofuran (8 mL). The mixture was stirred at 0°C for 1 hour to obtain reaction solution 1. Trimethylethynylsilane (2.3 g, 23.40 mmol) was dissolved in tetrahydrofuran (16 mL), cooled to -78°C, and n-butyllithium (2.5 M, 9.04 mL) in tetrahydrofuran was added dropwise. The mixture was stirred for 10 minutes to obtain reaction solution 2. Reaction solution 2 was added dropwise to reaction solution 1 and stirred at 40°C for 16 hours. The reaction solution was diluted with saturated ammonium chloride (20 mL) and extracted with ethyl acetate (20 mL x 3). The resulting organic phase was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (PE:EA = 1:0 to 8:1) to obtain B-8-3. 1 H NMR (400MHz, CDCl3) δ2.40 (s, 1H), 1.10-1.06 (m, 2H), 1.05-0.99 (m, 2H), 0.17 (s, 9H).

[0404] Step 3:

[0405] B-8-3 (0.5 g, 3.24 mmol) was dissolved in dichloromethane (1.0 mL). 3,4-Dihydro-2H-pyran (0.48 g, 5.7 mmol) and 4-methylbenzenesulfonate pyridinium (8.1 mg, 32.4 μmol) were then added sequentially. The mixture was stirred at 37°C for 16 hours. Triethylamine (0.05 mL) was added to the resulting reaction solution, which was then concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:0 to 99:1) to obtain B-8-4. 1 H NMR (400MHz, CDCl3) δ5.09–5.07(m,1H),3.93–3.87(m,1H),3.58–3.54(m,1H),1.78 –1.73(m,2H),1.58–1.54(m,4H),1.28–1.26(m,1H),1.06–1.00(m,3H),0.16(s,9H).

[0406] Step 4:

[0407] Dissolve B-8-4 (0.5 g, 2.10 mmol) and potassium carbonate (29.0 mg, 0.21 mmol) in methanol (5.0 mL) and stir at 25°C for 12 hours. The resulting reaction solution is concentrated under reduced pressure to obtain a crude product, which is then purified by column chromatography (PE:EA = 1:0 to 95:5) to obtain B-8. 1 H NMR (400MHz, CDCl3) δ5.11-5.04(m,1H),3.94-3.81(m,1H),3.62-3.49(m,1H),2.38 (s,1H),1.84-1.70(m,2H),1.58-1.53(m,4H),1.34-1.29(m,1H),1.12-0.99(m,3H).

[0408] Reference Example 9: Compound B-9

[0409] Step 1:

[0410] Dissolve B-9-1 (2.0 g, 13.68 mmol) in dichloromethane (50 mL), cool to 0°C, add Dess-Martin periodinane (7.0 g, 16.42 mmol), and heat to 25°C with stirring for 1 hour. The resulting reaction mixture is filtered, and the filtrate is concentrated under reduced pressure at 25°C and purified by column chromatography (PE:EA = 1:0 to 4:1) to obtain B-9-2. 1 H NMR (400MHz, CDCl3) δ9.75 (d, J = 2.2Hz, 1H), 3.19 (s, 3H), 3.15 (s, 3H), 2.96-2.85 (m, 1H), 2.39 (d, J = 8.3Hz, 4H).

[0411] Step 2:

[0412] Dissolve B-9-2 (1.0 g, 6.94 mmol) and (1-diazo-2-oxo-propanol)-phosphonic acid dimethyl ester (1.73 g, 9.02 mmol) in methanol (10 mL). Cool to 0°C, add potassium carbonate (3.8 g, 27.8 mmol), and stir at 0°C for half an hour. Dilute the reaction solution with water (20 mL) and extract with n-pentane (20 mL*2). The resulting organic phase is washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure at 25°C to obtain B-9. 1 H NMR (400MHz, CDCl3) δ3.16 (d, J = 2.2 Hz, 6H), 2.88-2.72 (m, 1H), 2.64-2.48 (m, 2H), 2.30-2.19 (m, 2H), 2.14 (d, J = 2.4Hz, 1H).

[0413] Reference Example 10: Compound B-10

[0414] Dissolve 5-fluoro-2-methoxyphenylmethanol (5.0 g, 32.02 mmol) in dichloromethane (50 mL). Cool to 0°C, then slowly add thionyl chloride (3.49 mL, 48.03 mmol) and N,N-dimethylformamide (0.25 mL, 3.20 mmol) dropwise. Stir at 0°C for 2 hours. The resulting reaction mixture is concentrated under reduced pressure to obtain B-10. 1 H NMR (400MHz, CDCl3) δ7.12 (dd, J = 3.1, 8.6 Hz, 1H), 7.00 (dt, J = 3.1, 8.5 Hz, 1H), 6.83 (dd, J = 4.4, 9.0 Hz, 1H), 4.62 (s, 2H), 3.87 (s, 3H).

[0415] Reference Example 11: Compound 001-3

[0416] Step 1:

[0417] Dissolve B-2 (5.0 g, 15.5 mmol), B-1 (3.58 g, 15.5 mmol), and potassium fluoride (3.15 g, 54.26 mmol) in dimethyl sulfoxide (50 mL), heat to 120°C, and stir for 1 hour. The reaction mixture was washed with 50 mL of water and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed sequentially with saturated brine (2 x 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (mobile phase PE:EA = 1:0 to 3:1) to obtain 001-1. LCMS: m / z = 517.2, 519.2 [M+H] + .

[0418] Step 2:

[0419] 001-1 (1.4 g, 2.71 mmol) was dissolved in DMF (15 mL). After nitrogen was replaced, cesium carbonate (2.65 g, 8.13 mmol) was added and stirred at 24°C for 2 hours. The reaction was quenched by adding 10 mL of water and extracted with EA (20 mL x 2). The resulting organic phase was washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by thin-layer chromatography (PE:EA = 1:1) to obtain 001-2. LCMS: m / z = 497.2, 499.2 [M+H] + .

[0420] Step 3:

[0421] 001-2 (1.1 g, 2.2 mmol) was dissolved in trifluoroacetic acid (2 mL) and heated to 70°C under a nitrogen atmosphere, with stirring for 12 hours. After the reaction mixture cooled to room temperature, 50 mL of water was added to quench the reaction. The mixture was extracted with EA (20 mL*3). The resulting organic phase was washed sequentially with saturated sodium bicarbonate (20 mL*3) and saturated brine (20 mL*3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 001-3. LCMS: m / z = 377.1, 379.1 [M+H] + .

[0422] Example 1

[0423] Step 1:

[0424] B-6 (977.71 mg, 5.57 mmol) and 001-3 (1.5 g, 3.98 mmol) were dissolved in DMF (15 mL), followed by the addition of potassium carbonate (1.65 g, 11.93 mmol) and stirring at 25°C for 16 hours. The reaction mixture was diluted with ice water (75 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed sequentially with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:0 to 3:1) to obtain 001-4. 1 H NMR (400MHz, CDCl3) δ8.24 (dd, J=3.0, 8.1Hz, 1H), 7.99 (s, 1H), 7.92(d,J=3.1Hz,1H),6.13-5.80(m,1H),5.34(d,J=14.5Hz,1H),4.59(d,J=11.9Hz,1H),4.54-4.4 1(m,3H),4.40-4.31(m,1H),4.04-3.96(m,4H),1.45(t,J=7.1Hz,3H), LCMS: m / z=516.1, 518.1[M+H] + .

[0425] Step 2:

[0426] 001-4 (1.5 g, 2.91 mmol) was added to a mixed solution of methanol (10 mL), tetrahydrofuran (10 mL), and ethanol (30 mL). The temperature was lowered to 0°C, and lithium hydroxide (2 M, 30.0 mL) was added. After stirring for half an hour, the temperature was slowly raised to 30°C and stirred for 14 hours. The reaction solution was diluted with water (1 mL), the pH value was adjusted to 3-4 with 2 M hydrochloric acid solution, and then extracted with ethyl acetate (20 mL * 3). The organic phases were combined, washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:0 to 1:1) to obtain 001-5. LCMS: m / z = 488.0, 490.1 [M+H] + .

[0427] Step 3:

[0428] 001-5 (0.6 g, 1.23 mmol) and N, N-diisopropylethylamine (0.64 mL, 3.69 mmol) were dissolved in tetrahydrofuran (12 mL), and then O-(7-azabenzotriazole-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate (0.61 g, 1.60 mmol) was added. After stirring for half an hour, B-7 (0.41 g, hydrochloride) was added and stirred at 25 ° C for 1 hour. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (20 mL * 3). The organic phases were combined, washed with saturated brine (10 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (PE: EA = 1:0 to 1:1) to obtain 001-6. 1 H NMR (400MHz, CDCl3) δ8.78(s,1H),8.02(d,J=2.9Hz,1H),7.78(d,J=8.3Hz,2H),7.66(d,J=7.0Hz,1H),7.52-7.47( m,3H),6.64-6.32(m,1H),5.15-5.02(m,1H),4.78-4.68(m,2H),4.63(d,J=12.0Hz,1H),4.52-4.43(m,1H),4.37(br dd,J=2.6,12.1Hz,1H),4.31-4.22(m,1H),3.85(s,3H),2.43(s,3H),2.30-2.16(m,2H),1.82-1.65(m,2H), LCMS: m / z=711.1, 713.1[M+H] + .

[0429] Step 4:

[0430] 001-6 (0.1 g, 0.14 mmol) was dissolved in acetonitrile (2 mL), and then 2,4,6-trimethylbenzenesulfonyl chloride (89.2 μL, 0.7 mmol) and sodium iodide (0.11 g, 0.7 mmol) were added and stirred at 25°C for 2 hours. The reaction solution was diluted with saturated aqueous sodium bicarbonate solution (2 mL), extracted with ethyl acetate (5 mL*3), and the organic phases were combined, washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by thin layer chromatography (PE:EA=0:1) to obtain 001-7. 1H NMR (400MHz, CDCl3) δ8.10(s,1H),7.75(d,J=8.2Hz,2H),7.59(d,J=5.4Hz,1H),7.44(dd,J=2.8,6.8Hz,1H),7.38-7.30(m,4H), 6.25-5.86(m,1H),5.19(d,J=16.5Hz,1H),5.09-4.99(m,1H),4.72-4.61(m,2H),4.50-4.40(m,1H),4.32-4.23(m,1H),4.18(br d, J=12.8Hz, 1H), 2.58-2.49 (m, 2H), 2.45 (s, 3H), 2.40-2.32 (m, 2H), LCMS: m / z=697.1, 699.1[M+H] + .

[0431] Step 5:

[0432] 001-7 (50.0 mg, 71.7 μmol) was dissolved in DMF (1 mL). Potassium carbonate (39.6 mg, 286.8 μmol) was added under nitrogen and stirred at 45°C for 2 hours. The reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL x 3). The combined organic phases were washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (PE:EA = 1:1) and then by preparative HPLC (column: Waters Xbridge BEH C18 100 x 30 mm x 10 μm; mobile phase A: 10 mM aqueous ammonium bicarbonate solution, mobile phase B: acetonitrile; gradient (mobile phase B): 20%-55%). The resulting eluate was concentrated under reduced pressure to remove most of the acetonitrile and then lyophilized to obtain 001. Chiral chromatography column detection [chromatographic column: Chiralpak IH-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 001 was 1.300 minutes, ee = 97.7%, and the retention time of the other isomer was 1.225 minutes. 1H NMR (400MHz, CDCl3) δ8.91(brd,J=9.6Hz,1H),8.10(s,1H),7.96(d,J=2.8Hz,1H),7.24(br d,J=2.4Hz,1H),6.26-5.91(m,1H),5.87(dd,J=1.1,16.0Hz,1H),5.18(q,J= 4.5Hz,1H),5.03-4.88(m,1H),4.77(d,J=12.1Hz,1H),4.38(td,J=1.9,11.9H z,1H),4.34-4.27(m,2H),3.12-3.03(m,1H),2.98-2.88(m,1H),2.26(dd,J= 7.8, 13.6Hz, 1H), 1.93 (dd, J=7.8, 14.2Hz, 1H), LCMS: m / z=525.0, 527.0[M+H] + .

[0433] Example 2

[0434] 001 (80.0 mg, 0.15 mmol) and cyclopropylacetylene (43.3 mg, 0.65 mmol) were dissolved in 1,4-dioxane (0.8 mL). Under a nitrogen atmosphere, a solution of diisopropylamine (25.8 μL, 0.18 mmol), bis(acetonitrile)palladium(II) chloride (1.2 mg, 4.6 μmol), tri-tert-butylphosphine (1.8 mg, 9.1 μmol) and cuprous iodide (0.58 mg, 30.5 μmol) in 1,4-dioxane (1.6 mL) was added, and the mixture was heated to 80 ° C and stirred for 48 hours. The resulting reaction solution was evaporated under reduced pressure to remove 1,4-dioxane and crudely purified by thin-layer chromatography (PE:EA = 1:1). The crude product was then purified by preparative HPLC (Xbridge Prep OBD C18 column, 150 x 40 mm x 10 μm; mobile phase A: 10 mM aqueous ammonium bicarbonate solution, mobile phase B: acetonitrile; gradient elution from mobile phase B 20% to 55%). Most of the acetonitrile was evaporated under reduced pressure and the product was lyophilized to yield 002. Chiral chromatography (Chiralpak IH-3 column, 50 x 4.6 mm ID, 3 μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7 M)]; phase B ratio increased from 5% to 50% in the first 1.2 minutes, maintained for 1 minute, and then decreased from 50% to 5% in the next 0.8 minutes) revealed a retention time of 1.224 minutes and an ee of 100.0%. 1H NMR (400MHz, CDCl3) δ8.91 (br d,J=10.3Hz,1H),8.07(s,1H),7.95(d,J=2.8Hz,1H),7.24(d,J=3.1Hz,1H),6.23-5.90 (m,1H),5.87(d,J=16.1Hz,1H),5.17(q,J=4.3Hz,1H),5.03-4.89(m,1H),4.75(d,J=12. 0Hz,1H),4.40-4.33(m,1H),4.32-4.24(m,2H),3.05(td,J=6.5,13.1Hz,1H),2.90(td, J=5.6,13.9Hz,1H),2.25(dd,J=7.6,13.4Hz,1H),1.91(dd,J=7.9,14.3Hz,1H),1.54(br s,1H),0.99-0.93(m,2H),0.93-0.85(m,2H), LCMS:m / z=511.2[M+H] + .

[0435] Example 3

[0436] Step 1:

[0437] 001-3 (0.9 g, 2.4 mmol) and B-4 (1.2 g, 3.7 mmol) were dissolved in N,N-dimethylformamide (9 mL), followed by the addition of cesium carbonate (2.3 g, 7.2 mmol) and stirring at 24°C for 1.5 hours. The reaction was quenched by the addition of 20 mL of water and extracted with EA (40 mL x 2). The resulting organic phase was washed with saturated brine (40 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 2:1) to obtain 003-1. LCMS: m / z = 694.2, 696.2 [M+Na] + .

[0438] Step 2:

[0439] Dissolve 003-1 (0.5 g, 0.74 mmol) in tetrahydrofuran (5 mL), methanol (5 mL), and ethanol (10 mL), then add lithium hydroxide monohydrate (2.5 g, 59.48 mmol) and stir at 24°C for 72 hours. Adjust the pH to 7-8 with 2M hydrochloric acid, extract with dichloromethane (40 mL x 2), wash with saturated brine (20 mL x 2), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain 003-2.

[0440] Step 3:

[0441] Dissolve 003-2 (0.1 g, 155.2 μmol) in ethyl acetate (1.0 mL). After nitrogen displacement, add hydrochloric acid / ethyl acetate solution (4 M, 0.5 mL) and react at 20°C for 1 hour. The resulting reaction solution is concentrated under reduced pressure to obtain the hydrochloride salt of 003-3. LCMS: m / z = 544.0, 546.0 [M+H] + .

[0442] Step 4:

[0443] 003-3 (42 mg, hydrochloride) was dissolved in dichloromethane (0.8 mL). Pentafluorophenyl diphenyl phosphate (44.47 mg, 115.74 μmol) and N,N-diisopropylethylamine (149.58 mg, 1.16 mmol) were added under a nitrogen atmosphere and stirred at 24°C for 12 hours. The reaction was quenched by the addition of 10 mL of water and extracted with dichloromethane (20 mL*3). The resulting organic phase was washed with saturated brine (20 mL*3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (dichloromethane:methanol = 20:1) and then separated by preparative high-performance liquid chromatography (column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase A: 10mM aqueous ammonium bicarbonate solution, mobile phase B: acetonitrile; gradient: phase B increased from 10% to 80% in the first 3 minutes, held for 0.9 minutes, and then decreased from 80% to 10% in the last 0.6 minutes) to obtain 003-4. 1 HNMR(400MHz,CDCl3)δppm 9.15(s,1H),8.04(s,1H),7.05-6.94(m,2H),6.86(dd,J=4.5,8.9Hz,1H),6.20-5.86(m,2H),4.73(d,J=12.0Hz,1H),4.43-4.3 4(m,1H),4.32-4.26(m,1H),4.24(d,J=15.1Hz,1H),4.00-3.87(m,2H),1.80(s,3H),1.62(s,3H); LCMS: m / z=526.1, 528.1[M+H] + .

[0444] Step 5:

[0445] 003-4 (0.1 g, 0.19 mmol) and B-8 (49.9 mg, 0.3 mmol) were dissolved in 1,4-dioxane (0.5 mL). Under a nitrogen atmosphere, a solution of diisopropylamine (113.6 μL, 0.80 mmol), bis(acetonitrile)palladium(II) chloride (8.0 mg, 30.8 μmol), tri-tert-butylphosphine (12.9 mg, 63.7 μmol) and cuprous iodide (4.0 mg, 21.1 μmol) in 1,4-dioxane (2.0 mL) was added, and the mixture was heated to 90 ° C and stirred for 12 hours. A solution of diisopropylamine (113.6 μL, 0.80 mmol), bis(acetonitrile)palladium(II) chloride (8.0 mg, 30.8 μmol), tri-tert-butylphosphine (12.9 mg, 63.7 μmol), and cuprous iodide (4.0 mg, 21.1 μmol) in 1,4-dioxane (1.5 mL) was then added and stirred at 90°C for 24 hours. The resulting reaction solution was concentrated under reduced pressure, and the residue was purified by thin-layer chromatography (PE:EA = 1:1) to afford 003-5. 1 H NMR(400MHz, CDCl3)δ9.07(s,1H),8.06-8.00(m,1H),7.01-6.96(m,2H),6.89-6.81(m,1H),6.23-5.95(m,1H),5.92-5.87(m,1H),4.76- 4.66(m,1H),4.42-4.32(m,1H),4.31-4.25(m,1H),4.24-4.19(m,1H),3.98-3.94(m,1H),3.90-3.85(m,1H),1.85-1.76(m,6H),1.61(br s,6H),1.46-1.40(m,2H),1.26(s,1H),1.22(s,2H),1.20(s,1H), LCMS: m / z=612.3[M+1] + .

[0446] Step 6:

[0447] 003-5 (50 mg, 81.8 μmol) was dissolved in tetrahydrofuran (1.25 mL). The mixture was cooled to 0°C and then added dropwise with ethyl acetate (4 M, 0.25 mL). The temperature was raised to 25°C and stirred for half an hour. Aqueous sodium bicarbonate (2 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3 mL x 3). The resulting organic phase was washed with saturated brine (3 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (PE:EA = 1:1) to obtain 003. Chiral chromatography column detection [chromatographic column: Chiralpak IH-3, 100×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 003 was 1.743 minutes, ee = 99.28%, and the retention time of the other isomer was 1.580 minutes. 1 H NMR (400MHz, CDCl3) δ9.22 (s, 1H), 8.03 (s, 1H), 7.28 (br s, 1H), 6.99 (d, J = 7.9Hz, 2H), 6.85 (br dd,J=4.2,9.4Hz,1H),6.11(dd,J=6.1,55.3Hz,1H),5.92-5.87(m,1H),4.72(br d,J=11.6Hz,1H),4.37(br d,J=6.8Hz,1H),4.31-4.27(m,1H),4.23(d,J=15.3Hz,1H),3.97(d,J=8.8Hz,1H),3.87(d,J=8.8H z,1H),1.79(s,3H),1.61(s,3H),1.20-1.18(m,2H),1.17(d,J=1.7Hz,2H), LCMS:m / z=528.1[M+1] + .

[0448] Example 4

[0449] Triethylamine trihydrofluoride (24.5 mg, 151.7 μmol) was dissolved in dichloromethane (0.4 mL). The mixture was cooled to -78°C, and triethylamine (10.6 μL, 75.8 μmol), diethylaminosulfur trifluoride (15.0 μL, 113.8 μmol), and a dichloromethane solution of 003 (40 mg, 75.8 μmol) were added. The mixture was stirred at -78°C for 1 hour, then slowly warmed to 20°C and stirred for 11 hours. The resulting reaction solution was purified by thin-layer chromatography (PE:EA = 2:3) and then by preparative chiral SFC separation [column: DAICEL CHIRALPAK IC (250 mm x 30 mm, 10 μm); mobile phase A: supercritical carbon dioxide, mobile phase B: ethanol (0.1% ammonia water), gradient elution: 45% mobile phase B]. Most of the ethanol was evaporated under reduced pressure, and the mixture was lyophilized to obtain 004. Chiral chromatography column detection [chromatographic column: Chiralpak IH-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: ethanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 004 ​​was 1.839 minutes, and the ee = 100.0%. 1 H NMR (400MHz, CDCl3) δ9.18 (s, 1H), 8.04 (s, 1H), 7.03-6.96 (m, 2H), 6.85 (dd, J = 4.4, 8. 8Hz,1H),6.20-6.02(m,1H),5.93-5.87(m,1H),4.73(d,J=11.9Hz,1H),4.41-4.33(m, 1H),4.33-4.26(m,1H),4.23(d,J=15.3Hz,1H),4.00-3.93(m,1H),3.91-3.84(m,1H), 1.81(s,3H),1.62(s,3H),1.45-1.37(m,2H),1.28-1.26(m,2H), LCMS: m / z=530.2[M+1] + .

[0450] Example 5

[0451] Step 1:

[0452] 001-3 (1.75 g, 4.64 mmol) was dissolved in N,N-dimethylformamide (17 mL). The temperature was cooled to 0°C, potassium carbonate (1.92 g, 13.92 mmol) was added, followed by a solution of B-5 (2.01 g, 6.03 mmol) in N,N-dimethylformamide (17 mL). After stirring at 0°C for half an hour, the temperature was slowly increased to 25°C, and the mixture was stirred for 11.5 hours. The reaction was quenched by adding 12 mL of water and extracted with ethyl acetate (20 mL x 3). The resulting organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:0 to 1:1) to obtain 005-1. 1 H NMR(400MHz, CDCl3)δ8.32(br d,J=6.4Hz,1H),8.01(s,1H),7.92(d,J=3.1Hz,1H),6.17-5.81(m,1H),5.50(d,J=14.4Hz,1H),4.65-4.39(m,7H),4.38-4.20(m,1H),3.94(br d, J=11.1Hz, 1H), 1.46-1.38 (m, 18H), LCMS: m / z=573.2, 575.2[M-100+H] + .

[0453] Step 2:

[0454] A dichloromethane solution of boron tribromide (2M, 3.59 mL) was diluted with 5.0 mL of dichloromethane and cooled to -78°C. A dichloromethane solution of 005-1 (0.97 g, 1.44 mmol) was added dropwise, and the temperature was slowly raised to 25°C with stirring for 12 hours. The resulting reaction solution was concentrated under reduced pressure at 30°C, and N,N-diisopropylethylamine (20.0 mL) was added to afford 005-2. LCMS: m / z = 545.2, 547.2 [M+H] + .

[0455] Step 3:

[0456] 005-2 (0.78 g, 1.44 mmol) was dissolved in dichloromethane (15.6 mL), followed by the addition of 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate (1.12 g, 2.15 mmol) and N,N-diisopropylethylamine (2.5 mL, 14.36 mmol), and stirred at 25°C for 2 hours. The reaction was quenched by the addition of water (10 mL), and extracted with dichloromethane (20 mL*3). The resulting organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:0 to 1:1) to obtain 005-3. LCMS: m / z = 527.1, 529.1 [M+H] + .

[0457] Step 4:

[0458] 005-3 (40.0 mg, 75.9 μmol), cyclopropylacetylene (15.0 mg, 0.23 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (12.8 mg, 15.2 μmol), and cuprous iodide (2.89 mg, 15.2 μmol) were added to acetonitrile (1.0 mL), followed by diisopropylamine (0.4 mL, 2.83 mmol). The mixture was heated to 90°C and stirred for 12 hours under a nitrogen atmosphere. The reaction was quenched by the addition of water (10 mL) and extracted with ethyl acetate (20 mL*3). The resulting organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:0 to 1:1) and preparative HPLC (Waters Xbridge BEH C18 100 x 30 mm x 10 μm column; mobile phase A: 10 mM aqueous ammonium bicarbonate, mobile phase B: acetonitrile; gradient elution from 30% to 65% mobile phase B). The acetonitrile was evaporated under reduced pressure, and the product was lyophilized to yield 005. Chiral chromatography (Chiralpak IH-3 column, 50 x 4.6 mm ID, 3 μm column; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7 M)]; phase B ratio increased from 5% to 50% in the first 1.2 minutes, maintained for 1 minute, and then decreased from 50% to 5% in the next 0.8 minutes) revealed a retention time of 005 of 1.277 minutes and an ee of 95.58%. The other isomer had a retention time of 1.426 minutes. 1H NMR (400MHz, CDCl3) δ8.87(br s,1H),8.00(br d,J=16.5Hz,2H),7.33(br d,J=7.2Hz,1H),6.21-5.88(m,1H),5.71(br d,J=15.3Hz,1H),4.79(br d,J=10.6Hz,1H),4.71(br d,J=11.6Hz,1H),4.27(br d,J=15.3Hz,3H),3.87(br d,J=10.4Hz,1H),1.80(s,3H),1.61(br s,3H),1.26(br s,1H),0.96-0.84(m,4H), LCMS:m / z=513.2[M+H] + .

[0459] Example 6

[0460] 005-3 (40.0 mg, 75.9 μmol), 3-ethynyloxetane (12.5 mg, 0.15 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl) (2'-amino-1,1'-biphenyl-2-yl) palladium (II) (12.8 mg, 15.2 μmol) and cuprous iodide (2.2 mg, 11.4 μmol) were added to acetonitrile (0.8 mL), and then diisopropylamine (0.4 mL, 2.83 mmol) was added. The temperature was raised to 90 ° C and stirred for 12 hours under a nitrogen atmosphere. The resulting reaction solution was concentrated under reduced pressure to obtain a crude product, which was purified by thin-layer chromatography (EA:DCM=1:1) and then by preparative high-performance liquid chromatography [column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase A: 10mM aqueous ammonium bicarbonate solution, mobile phase B: acetonitrile; mobile phase B 30%-60% gradient elution]. Most of the acetonitrile was evaporated under reduced pressure, and the product was lyophilized to obtain 006. Chiral chromatography column detection [chromatographic column: Chiralpak IH-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 006 was 1.128 minutes, ee = 92.62%, and the retention time of the other isomer was 1.255 minutes. 1H NMR(400MHz, CDCl3)δ8.92(s,1H),8.07(s,1H), 8.00(d,J=2.9Hz,1H),7.34(dd,J=2.6,7.4Hz,1H),6.21-5.88(m,1H),5.76-5.68(m,1H),4.96-4.89(m,2H),4.87-4.77(m,3H),4.73(br d,J=11.5Hz,1H),4.35-4.21(m,4H),3.88(d,J=10.5Hz,1H),3.27-3.17(m,1H),1.79(s,3H),1.62(s,3H), LCMS:m / z=529.2[M+H] + .

[0461] Example 7

[0462] Step 1:

[0463] 005-3 (20 mg, 37.9 μmol), B-8 (12.6 mg, 75.9 μmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium (II) (6.4 mg, 7.6 μmol) and cuprous iodide (1.1 mg, 5.8 μmol) were added to acetonitrile (0.4 mL), followed by diisopropylamine (0.2 mL, 1.42 mmol). The mixture was heated to 90°C and stirred for 12 hours under a nitrogen atmosphere. The resulting reaction solution was concentrated under reduced pressure to obtain a crude product, which was purified by thin-layer chromatography (PE:EA=1:2) to obtain 007-1. LCMS: m / z=613.2 [M+H] + .

[0464] Step 2:

[0465] 007-1 (40 mg, 65.3 μmol) was dissolved in tetrahydrofuran (2.0 mL). The temperature was cooled to 0°C, and a solution of ethyl acetate (4 M, 0.4 mL) was added dropwise. The temperature was raised to 25°C and stirred for 2 hours. The reaction was quenched by the addition of water (2 mL), and extracted with dichloromethane (5 mL x 3). The resulting organic phase was washed with saturated brine (3 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (PE:EA = 1:1) to obtain 007. Chiral chromatography column detection [chromatographic column: Chiralpak IH-3, 100×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 007 was 1.099 minutes, and the ee = 100.0%. 1 H NMR (400MHz, CDCl3) δ8.93(s,1H),8.04(s,1H),8.00(d,J=2.9Hz,1H),7.34(dd,J=2.8,7. 8Hz,1H),6.21-5.89(m,1H),5.72(dd,J=1.5,15.4Hz,1H),4.79(d,J=10.8Hz,1H),4.73(br d,J=12.0Hz,1H),4.35-4.23(m,3H),3.88(d,J=10.5Hz,1H),1.62(s,3H),1.26(s,3H),1.20-1.14(m,4H), LCMS: m / z=529.2[M+H] + .

[0466] Example 8

[0467] Compound 003-4 and 3-ethynyloxetane were used as raw materials and 008 was obtained by referring to the synthesis method of the above examples. Characterization of 008: Chiral chromatography column detection [chromatographic column: Chiralpak OJ-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes, maintained for 1 minute, and then decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 008 was 1.270 minutes, ee = 95.92%, and the retention time of the other isomer was 1.198 minutes. 1H NMR(400MHz, CDCl3)δ9.21(s,1H),8.05(s,1H),7.04-6.93(m,2H),6.86(br dd,J=4.3,8.8Hz,1H),6.21-5.86(m,2H),4.97-4.88(m,2H),4.87-4.81(m,2H),4.73(br d,J=12.0Hz,1H),4.41-4.34(m,1H),4.33-4.19(m,3H),3.99-3.93(m,1H),3.91-3.86(m,1H),1.80(s,3H),1.61(s,3H), LCMS:m / z=528.1[M+H] + .

[0468] Example 9

[0469] Compound 003-4 and 4-ethynyltetrahydro-2H-pyran were used as starting materials and 009 was obtained by referring to the synthesis method of the above examples. Characterization of 009: Chiral chromatography column detection [chromatographic column: Chiralpak IH-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes, maintained for 1 minute, and then decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 009 was 1.184 minutes, ee = 93.86%, and the retention time of the other isomer was 1.283 minutes. 1 H NMR (400MHz, CDCl3) δ9.08(s,1H),7.96(s,1H),6.97-6.83(m,2H),6.77(br dd,J=4.3,9.9Hz,1H),6.13-5.79(m,2H),4.64(br d,J=11.9Hz,1H),4.29(br d,J=6.9Hz,1H),4.23-4.12(m,2H),3.94-3.86(m,3H),3.83-3.77(m,1H),3.50-3.40(m,2H) ),2.91(tt,J=4.1,8.6Hz,1H),1.92-1.86(m,2H),1.84-1.77(m,2H),1.73(s,3H),1.54(br s,3H), LCMS: m / z=556.3[M+H] + .

[0470] Example 10

[0471] 005-3 (40.0 mg, 75.9 μmol), acetamide (9.0 mg, 151.7 μmol), potassium phosphate (48.3 mg, 227.6 μmol), (1S,2S)-(+)-N,N-dimethylcyclohexane-1,2-diamine (8.6 mg, 60.7 μmol) and cuprous iodide (5.8 mg, 30.3 μmol) were added to 1,4-dioxane (0.8 mL), and the temperature was raised to 80 ° C and stirred for 12 hours under a nitrogen atmosphere. The resulting reaction solution was concentrated under reduced pressure to obtain a crude product, which was then purified by thin-layer chromatography (DCM:EA=1:1) and then by preparative high-performance liquid chromatography [chromatographic column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase A: 10mM aqueous ammonium bicarbonate solution, mobile phase B: acetonitrile; mobile phase B 37%-62% gradient elution]. The liquid fraction was evaporated under reduced pressure to remove most of the acetonitrile, and then lyophilized to obtain 010. Chiral chromatographic column detection [chromatographic column: Chiralpak AD-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 10% to 50% in the first 3.5 minutes and maintained for 1 minute, and then the proportion of phase B decreased from 50% to 10% in the next 0.5 minutes] showed that the retention time of 010 was 3.423 minutes, ee = 93.18%, and the retention time of the other isomer was 3.642 minutes. 1 H NMR (400MHz, CDCl3) δ10.32-9.95(m,1H),9.00(br s,1H),8.19(br s,1H),7.99(br s,1H),7.41-7.32(m,1H),6.23-5.57(m,2H),4.96-4.78(m,1H),4.77-4.61(m,1H),4.42-4.14(m,3H),3.98-3.84(m,1H),2.26(br s,3H),1.77(br s,3H),1.62(br s,3H), LCMS: m / z=506.2[M+H] + .

[0472] Example 11

[0473] 003-4 and methyl propargyl ether (10.0 mg, 0.14 mmol) were dissolved in 1,4-dioxane (0.1 mL). Under nitrogen atmosphere, a solution of diisopropylamine (22.8 μL, 0.16 mmol), bis(acetonitrile)palladium(II) chloride (1.6 mg, 6.2 μmol), tri-tert-butylphosphine (2.6 mg, 12.7 μmol) and cuprous iodide (0.8 mg, 4.2 μmol) in 1,4-dioxane (0.4 mL) was added. The mixture was stirred at 25 °C for 1 hour, then heated to 90 °C and stirred for 12 hours. Methyl propargyl ether (10.0 mg, 0.14 mmol) was added, and under a nitrogen atmosphere, a solution of diisopropylamine (22.8 μL, 0.16 mmol), bis(acetonitrile)palladium(II) chloride (1.6 mg, 6.2 μmol), tri-tert-butylphosphine (2.6 mg, 12.7 μmol) and cuprous iodide (0.8 mg, 4.2 μmol) in 1,4-dioxane (0.3 mL) was added, and the mixture was stirred at 90 °C for 12 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then purified by thin-layer chromatography (PE:EA=1:1) and preparative HPLC [column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase A: 10mM aqueous ammonium bicarbonate solution, mobile phase B: acetonitrile; gradient elution: mobile phase B 25%-65%]. The organic fraction was evaporated under reduced pressure to remove most of the acetonitrile, and then lyophilized to obtain 011. Characterization of 011: Chiral chromatography column analysis [column: Chiralcel OJ-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the B ratio increased from 5% to 50% in the first 1.2 minutes, maintained for 1 minute, and then decreased from 50% to 5% in the next 0.8 minutes] showed a retention time of 1.360 minutes for 011, with an ee of 100.0%. 1 H NMR (400MHz, CDCl3) δ9.18 (s, 1H), 8.06 (s, 1H), 7.03-6.96 (m, 2H), 6.86 (dd, J = 4.3, 8. 7Hz,1H),6.11(dd,J=6.3,55.5Hz,1H),5.92-5.87(m,1H),4.73(d,J=12.1Hz,1H),4.4 4(s,2H),4.40-4.34(m,1H),4.32-4.27(m,1H),4.23(d,J=15.5Hz,1H),3.99-3.95(m, 1H), 3.91-3.86 (m, 1H), 3.50 (s, 3H), 1.81 (s, 3H), 1.62 (s, 3H), LCMS: m / z=516.3[M+H] + .

[0474] Example 12

[0475] Step 1:

[0476] 003-4 (0.1 g, 0.19 mmol) and triisopropylsilyl acetylene (86.6 mg, 0.48 mmol) were dissolved in acetonitrile (2.5 mL). Diisopropylamine (1.0 mL, 7.08 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium (II) (32.2 mg, 38.0 μmol) and cuprous iodide (10.9 mg, 57.0 μmol) were added under nitrogen atmosphere and stirred at 90°C for 16 hours. The resulting reaction solution was concentrated under reduced pressure to obtain a crude product, which was purified by thin layer chromatography (PE:EA=1:1) to obtain 012-1. 1 H NMR(400MHz, CDCl3)δ8.94(s,1H),8.06(s,1H),7.02-6.94(m,2H),6.87-6.78 (m,1H),6.21-5.87(m,2H),4.71(d,J=11.9Hz,1H),4.39-4.32(m,1H),4.28(br dd,J=1.8,12.1Hz,1H),4.21(d,J=15.3Hz,1H),3.98-3.92(m,1H),3.91-3.84 (m,1H),1.79(s,3H),1.61(s,3H),1.31-1.16(m,21H), LCMS: m / z=628.3[M+H] + .

[0477] Step 2:

[0478] 012-1 (0.13 g, 0.21 mmol) and cesium fluoride (0.16 g, 1.04 mmol) were dissolved in N,N-dimethylformamide (2.5 mL) and stirred at 25°C for 1 hour. The reaction was quenched by the addition of water (10 mL) and extracted with ethyl acetate (10 mL x 3). The resulting organic phase was washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (PE:EA = 1:0 to 1:1) to obtain 012-2. 11H NMR (400 MHz, CDCl3) δ 9.20 (s, 1H), 8.06 (s, 1H), 7.04 - 6.95 (m, 2H), 6.86 (dd, J = 4.3, 8.9 Hz, 1H), 6.22 - 5.83 (m, 2H), 4.73 (d, J = 11.7 Hz, 1H), 4.43 - 4.34 (m, 1H), 4.34 - 4.28 (m, 1H), 4.24 (d, J = 15.3 Hz, 1H), 4.00 - 3.95 (m, 1H), 3.92 - 3.87 (m, 1H), 3.46 (s, 1H), 1.81 (s, 3H), 1.62 (s, 3H), LCMS: m / z = 472.2 [M + H] + .

[0479] Step 3:

[0480] 012-2 (35 mg, 74.2 μmol) was dissolved in N,N-dimethylformamide (0.7 mL), cooled to 0°C, and a solution of (trifluoromethyl)trimethylsilane (21.1 mg, 148.4 μmol) in N,N-dimethylformamide (0.1 mL) was added dropwise to obtain reaction solution 1. Cuprous iodide (21.2 mg, 111.4 μmol), potassium carbonate (30.8 mg, 222.7 μmol), and tetramethylethylenediamine (16.8 μL, 111.4 μmol) were dissolved in N,N-dimethylformamide (0.7 mL), stirred for 15 minutes, and a solution of (trifluoromethyl)trimethylsilane (21.1 mg, 148.4 μmol) in N,N-dimethylformamide (0.1 mL) was added dropwise to obtain reaction solution 2. Reaction solution 1 was slowly added dropwise to reaction solution 2, and stirred at 0°C for 1.5 hours. The reaction was quenched by adding water (10 mL) and extracted with ethyl acetate (10 mL * 3). The resulting organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by thin-layer chromatography (PE:EA = 1:0 to 2:1) and then by preparative high-performance liquid chromatography [chromatographic column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase A: 10mM ammonium bicarbonate aqueous solution, mobile phase B: acetonitrile; mobile phase B 45%-75% gradient elution], and the obtained organic fraction was evaporated under reduced pressure to remove most of the acetonitrile, and then lyophilized to obtain 012. Chiral chromatographic column detection [chromatographic column: Chiralcel OJ-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: ethanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 10% to 50% in the first 3.5 minutes and maintained for 1 minute, and then the proportion of phase B decreased from 50% to 10% in the next 0.5 minutes] showed that the retention time of 012 was 3.417 minutes, ee = 97.86%, and the retention time of the other isomer was 3.091 minutes. 1 H NMR(400MHz, CDCl3)δ9.20(s,1H),8.08(s,1H),7.06-6.94(m,2H),6.86(dd,J=4.4,8.9Hz,1H),6.22-5.84(m,2H),4.76(d,J=12.1Hz,1H),4.44-4 .36(m,1H),4.35-4.29(m,1H),4.26(d,J=15.4Hz,1H),3.98(d,J=8.8Hz, 1H), 3.93-3.85 (m, 1H), 1.81 (s, 3H), 1.62 (s, 3H), LCMS: m / z=540.1[M+H] + .

[0481] Example 13

[0482] Step 1:

[0483] 003-4 (45 mg, 85.5 μmol) and B-9 (47.9 mg, 0.34 mmol) were dissolved in acetonitrile (1.3 mL). Diisopropylamine (0.45 mL, 3.18 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium (II) (14.5 mg, 17.1 μmol), and cuprous iodide (4.9 mg, 25.7 μmol) were added under nitrogen atmosphere. The mixture was stirred at 90°C for 22 hours. The resulting reaction solution was concentrated under reduced pressure to obtain a crude product, which was purified by thin-layer chromatography (PE:EA=1:1) to obtain 013-1. LCMS: m / z=586.3 [M+H] + .

[0484] Step 2:

[0485] 013-1 (110 mg, 0.19 mmol) and a solution of hydrochloric acid (2 M, 0.47 mL) in ethyl acetate were added to tetrahydrofuran (0.5 mL) and stirred at 25°C for 1 hour. The resulting reaction solution was concentrated under reduced pressure to obtain 013-2. 1 H NMR (400MHz, CDCl3) δ9.18(s,1H),8.03(s,1H),6.99-6.97(m,2H),6.86(br d,J=4.4Hz,1H),6.19-5.92(m,2H),4.71(br d,J=3.9Hz,1H),4.37(br d,J=2.5Hz,1H),4.31-4.29(m,1H),4.21(d,J=4.5Hz,1H),3.95(d,J=4.0Hz,1H),3.89(d,J=3.5Hz,1H),3.57-3.43(m,5H),1.81(s,3H),1.61(br s,3H), LCMS: m / z=540.2[M+H] + .

[0486] Step 3:

[0487] Dissolve 013-2 (0.12 g, 0.22 mmol) in dichloromethane (1.0 mL). Cool to 0°C, then add a solution of (2-methoxyethyl)aminosulfur trifluoride (1.22 mL, 5.56 mmol) in dichloromethane (0.5 mL) dropwise. Stir at 0°C for 1 hour, then warm to 25°C and stir for 3 hours. Quench the reaction with water (5 mL), extract with dichloromethane (5 mL x 3), and wash the resulting organic phase with saturated brine (2 mL), dry over anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure to yield the crude product. The crude product was purified by thin-layer chromatography (PE:EA=1:0 to 1:1) and then by preparative high-performance liquid chromatography [chromatographic column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase A: 10mM aqueous ammonium bicarbonate solution, mobile phase B: acetonitrile; mobile phase B 40%-70% gradient elution]. The resulting organic fraction was evaporated under reduced pressure to remove most of the acetonitrile, and then lyophilized to obtain 013. Chiral chromatography column detection [chromatographic column: Chiralcel OJ-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: ethanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 10% to 50% in the first 3.5 minutes and maintained for 1 minute, and then the proportion of phase B decreased from 50% to 10% in the next 0.5 minutes] showed that the retention time of 013 was 3.586 minutes, ee = 98.52%, and the retention time of the other isomer was 3.269 minutes. 1 H NMR (400MHz, CDCl3) δ9.20 (s, 1H), 8.04 (s, 1H), 7.04-6.96 (m, 2H), 6.85 (dd, J = 4. 3,9.1Hz,1H),6.21-5.83(m,2H),4.73(d,J=11.5Hz,1H),4.43-4.33(m,1H),4.33 -4.26(m,1H),4.23(d,J=15.4Hz,1H),4.00-3.94(m,1H),3.92-3.85(m,1H),3.31 -3.19(m,1H),3.04-2.80(m,4H),1.81(s,3H),1.61(s,3H), LCMS: m / z=562.2[M+H] + .

[0488] Example 14

[0489] 010 (25 mg, 49.5 μmol) was dissolved in ethanol (0.2 mL). Under a nitrogen atmosphere, a solution of hydrochloric acid (12 M, 0.2 mL) in ethanol was added and stirred at 85°C for 1.5 hours. After cooling to room temperature, the reaction was quenched by the addition of water (3 mL). The pH was adjusted to 7-8 with 2 M aqueous sodium hydroxide solution. The mixture was extracted with ethyl acetate (5 mL x 3). The resulting organic phase was washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (EA:DCM = 10:1) to obtain 014. Chiral chromatographic column detection [chromatographic column: Chiralpak AD-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: isopropanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and maintained for 1 minute, and then decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 014 was 1.321 minutes, ee = 91.5%, and the retention time of the other isomer was 1.460 minutes. 1 H NMR (400MHz, CDCl3) δ8.80(s,1H),7.98(d,J=2.9Hz,1H),7.89(s,1H),7.32(dd,J=2.8,7.8Hz,1H), 6.17-5.84(m,1H),5.66(dd,J=1.4,15.4Hz,1H),5.46-4.98(m,2H),4.85(d,J=10.5Hz,1H),4.67(br d,J=11.8Hz,1H),4.28-4.19(m,3H),3.88(d,J=10.6Hz,1H),1.77(s,3H),1.62(s,3H), LCMS:m / z=464.2[M+H] + .

[0490] Example 15

[0491] Step 1:

[0492] 010 (30 mg, 59.4 μmol) and cesium carbonate (29 mg, 89.0 μmol) were dissolved in N,N-dimethylformamide (0.3 mL). After stirring for half an hour, iodomethane (5.6 μL, 89.0 μmol) was added and stirred at 20°C for 3.0 hours. After cooling to room temperature, water (2 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (2 mL x 3). The resulting organic phase was washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 015-1. LCMS: m / z = 520.3 [M+H] + .

[0493] Step 2:

[0494] 015-1 (30 mg, 57.8 μmol) was dissolved in ethanol (0.1 mL). Under a nitrogen atmosphere, a solution of hydrochloric acid (12 M, 0.3 mL) in ethanol was added and stirred at 85°C for 1.0 hour. After cooling to room temperature, the reaction was quenched by the addition of water (3 mL). The pH was adjusted to 7-8 with 2 M aqueous sodium hydroxide solution. The mixture was extracted with ethyl acetate (5 mL x 3). The resulting organic phase was washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (PE:EA = 1:1) to obtain 015. Chiral chromatographic column detection [chromatographic column: Chiralpak AD-3, 50×4.6mm ID, 3um; mobile phase A: supercritical carbon dioxide, mobile phase B: isopropanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 015 was 1.155 minutes, ee = 89.6%, and the retention time of the other isomer was 1.260 minutes. 1 H NMR (400MHz, CDCl3) δ8.78(s,1H),8.02(s,1H),7.98(d,J=2.8Hz,1H),7.32(dd,J=2.7,7. 8Hz,1H),6.16-5.85(m,1H),5.65(dd,J=1.3,15.4Hz,1H),4.84(d,J=10.8Hz,1H),4.67(br d,J=11.8Hz,1H),4.28-4.19(m,3H),3.88(d,J=10.5Hz,1H),2.98(s,3H),1.75(s,3H),1.60(s,3H), LCMS: m / z=478.2[M+H] + .

[0495] Example 16

[0496] 003-4 (40 mg, 76.0 μmol), a methanol solution (0.4 mL) of 3-methoxy-3-methyl-1-butyne (14.9 mg, 152.0 μmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium (II) (12.9 mg, 15.2 μmol) and cuprous iodide (2.9 mg, 15.2 μmol) were added to acetonitrile (0.2 mL) in sequence. Diisopropylamine (0.4 mL, 2.83 mmol) was added under a nitrogen atmosphere, and the temperature was raised to 90 ° C and stirred for 12 hours. The resulting reaction solution was concentrated under reduced pressure to obtain a crude product, which was then purified by thin-layer chromatography (PE:EA=2:3) to obtain 016. Characterization of 016: Chiral column detection [chromatographic column: Chiralpak IH-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 016 was 1.022 minutes, ee=93.1%, and the retention time of the other isomer was 1.100 minutes. 1 HNMR(400MHz, CDCl3)δ9.09(s,1H),8.04(s,1H),7.03-6.95(m,2H),6.88-6 .81(m,1H),6.20-5.88(m,2H),4.72(d,J=11.9Hz,1H),4.40-4.32(m,1H),4. 28(td,J=2.0,11.9Hz,1H),4.22(d,J=15.3Hz,1H),3.98-3.92(m,1H),3.89 -3.84(m,1H),3.54(s,3H),1.80(s,3H),1.61(s,9H), LCMS: m / z=544.3[M+H] + .

[0497] Example 17

[0498] Dissolve triethylamine trihydrofluoride (54.9 mg, 340.6 μmol) in dichloromethane (0.9 mL), cool to -78°C, add triethylamine (23.7 μL, 170.3 μmol), diethylaminosulfur trifluoride (33.8 μL, 255.5 μmol) and a dichloromethane (0.9 mL) solution of compound 007 (90 mg, 170.3 μmol), slowly warm to 20°C and stir for 12 hours. The resulting reaction solution was purified by thin-layer chromatography (PE:EA=1:1) and then by chiral SFC separation [chromatographic column: DAICEL CHIRALPAK IC (250 mm*30 mm, 10 μm); mobile phase A: supercritical carbon dioxide, mobile phase B: ethanol, mobile phase B: 50% gradient elution], concentrated under reduced pressure, and then lyophilized to obtain 017. Characterization of 017: Chiral chromatography column detection [chromatographic column: OZ-3, 100×4.6 mm ID, 3 μm; mobile phase A: supercritical CO2, mobile phase B: methanol [0.2% NH3 / MeOH (7 M)]; gradient: A:B=70:30] showed that the retention time of 017 was 2.019 minutes, the ee was 96.18%, and the retention time of the other isomer was 2.829 minutes. 1 H NMR (400MHz, CDCl3) δ8.88(s,1H),8.06(s,1H),7.99(d,J=2.9Hz,1H),7.34(dd,J=2.9, 7.8Hz,1H),6.21-5.89(m,1H),5.72(d,J=15.5Hz,1H),4.78(d,J=10.6Hz,1H),4.73(br d,J=11.6Hz,1H),4.36-4.24(m,3H),3.88(d,J=10.5Hz,1H),1.79(s,3H), 1.62(s,3H),1.45-1.37(m,2H),1.30-1.26(m,2H), LCMS: m / z=531.2[M+1] + .

[0499] Example 18

[0500] 005-3 (0.1 g, 189.7 μmol), methanesulfonic acid (2-cyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium (II) (32.1 mg, 37.9 μmol) and cuprous iodide (10.8 mg, 56.9 μmol) were added to acetonitrile (2.0 mL), and a solution of diisopropylamine (716.0 mg, 1.0 mL) and 3-methoxy-3-methylbut-1-yne (37.2 mg, 379.3 μmol) in methanol (0.5 mL) was added under a nitrogen atmosphere, and then the temperature was slowly raised to 60 ° C and stirred for 12 hours. The resulting reaction solution was concentrated under reduced pressure to obtain a crude product, which was then purified by thin-layer chromatography (developing solvent: PE:EA = 1:1) and preparative high-performance liquid chromatography (column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase A: 10mM aqueous ammonium bicarbonate solution, mobile phase B: acetonitrile, mobile phase B gradient: 35%-65%) to obtain 018. Characterization of 018: Chiral chromatography column analysis [Chiralpak AD-3, 150×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: isopropanol [0.2% NH3 / MeOH (7M)]; phase B ratio increased from 10% to 50% in the first 3.5 minutes, maintained for 1 minute, and then decreased from 50% to 10% in the next 0.5 minutes] showed a retention time of 2.868 minutes for 018, an ee of 91.68%, and a retention time of 3.145 minutes for the other isomer. 1 H NMR (400MHz, CDCl3) δ8.78(s,1H),8.05(s,1H),7.98(d,J=2.9Hz,1H),7.34(dd,J=2.8,7. 8Hz,1H),6.21-5.90(m,1H),5.73(dd,J=1.1,15.4Hz,1H),4.77(d,J=10.5Hz,1H),4.72(br d,J=11.9Hz,1H),4.36-4.22(m,3H),3.88(d,J=10.5Hz,1H),3.53(s,3H),1.79(s,3H),1.63(s,3H),1.61(d,J=1.3Hz,6H), LCMS: m / z=545.2[M+1] + .

[0501] Example 19

[0502] Compound 001 and 3-methoxy-3-methylbut-1-yne were used as raw materials and 019 was obtained by referring to the synthesis method of the above embodiment. Characterization of 019: Chiral chromatography column detection [chromatographic column: Chiralpak IH-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes, maintained for 1 minute, and then decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 019 was 1.112 minutes, and the ee = 100.0%. 1 H NMR (400MHz, CDCl3) δ8.94(br d,J=10.4Hz,1H),8.10(s,1H),7.96(d,J=2.4Hz,1H),7.25(br s,1H),6.24-5.92(m,1H),5.88(br d,J=16.0Hz,1H),5.17(q,J=4.4Hz,1H),5.02-4.92(m,1H),4.76(br d,J=11.8Hz,1H),4.38(br d,J=11.1Hz,1H),4.34-4.25(m,2H),3.54(s,3H),3.11-2.98(m,1H),2.95-2.84(m,1H),2.2 5(dd,J=7.9,13.6Hz,1H),1.92(dd,J=7.9,13.8Hz,1H),1.56(s,6H), LCMS: m / z=543.3[M+1] + .

[0503] Example 20

[0504] Compound 001 and B-8 were used as raw materials and 020 was obtained according to the synthesis method of the above examples. Characterization of 020: Chiral color detection [chromatographic column: Chiralcel OJ-3, 50×4.6 mm ID, 3 μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7 M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 020 was 1.250 minutes, and the ee = 100.0%. 1H NMR (400MHz, CDCl3) δppm 8.94 (br d,J=10.4Hz,1H),8.08(s,1H),7.96(d,J=2.9Hz,1H),7.25(d,J=2.9Hz,1H),6.25- 5.92(m,1H),5.91-5.82(m,1H),5.18(q,J=4.4Hz,1H),5.01-4.89(m,1H),4.76(br d,J=11.9Hz,1H),4.43-4.34(m,1H),4.34-4.25(m,2H),3.13-3.00(m,1H),2.90(td,J=5.6,14.1Hz,1H),2.26(d d,J=7.8,13.8Hz,1H),1.92(dd,J=7.8,14.0Hz,1H),1.24-1.19(m,2H),1.19-1.14(m,2H), LCMS:m / z=527.1[M+1] + .

[0505] Example 21

[0506] Compound 021 was obtained using compound 020 as the starting material and referring to the synthesis method of the above embodiment. Characterization of 021: Chiral chromatography column detection [chromatographic column: Chiralpak IC-3, 50×4.6 mm ID, 3 μm; mobile phase A: supercritical carbon dioxide, mobile phase B: ethanol [0.2% NH3 / MeOH (7 M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 021 was 2.007 minutes, and the ee = 100.0%. 1 H NMR (400MHz, CDCl3) δ8.92(br d,J=10.5Hz,1H),8.07(s,1H),7.94(d,J=2.6Hz,1H),7.26(br s,1H),6.31-5.95(m,1H),5.86(br d,J=15.9Hz,1H),5.17(q,J=4.4Hz,1H),5.01-4.84(m,1H),4.77(br d,J=11.9Hz,1H),4.43-4.24(m,3H),3.14-2.98(m,1H),2.89(td,J=5.5,13.7Hz,1H),2.28(br dd,J=7.8,13.5Hz,1H),1.90(br dd,J=7.8,14.1Hz,1H),1.49-1.34(m,2H),1.31-1.23(m,2H), LCMS:m / z=529.2[M+1]+ .

[0507] Example 22

[0508] Step 1:

[0509] 001-3 (4.0 g, 10.61 mmol) was dissolved in DMF (40 mL), followed by the addition of potassium carbonate (2.20 g, 15.91 mmol) and B-10 (2.04 g, 11.67 mmol). The mixture was stirred at 45°C for 12 hours. The reaction mixture was diluted with water (40 mL) and extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 10:1 to 1:1) to obtain 022-1. 1 H NMR(400MHz, CDCl3)δ7.99(s,1H),7.67(dd,J=3.1,8.8Hz,1H),7.00-6.92(m,1H),6.83(dd,J=4.3,9.0Hz,1H),6.13-5.78(m,1H),5.51(d, J=14.5Hz,1H),4.63-4.38(m,4H),4.30-4.16(m,1H),3.98-3.91(m,1H),3.86(s,3H),1.44(t,J=7.1Hz,3H), LCMS: m / z=514.9, 516.9[M+H] + Step 2:

[0510] Boron tribromide (2.0M dichloromethane solution, 19.41mL) was added to dichloromethane (40mL). The temperature was cooled to 0°C, and a solution of 022-1 (4g, 7.76mmol) in dichloromethane (40mL) was added dropwise. The mixture was stirred at 25°C for 12 hours. The reaction mixture was cooled to 0°C, and additional boron tribromide (2M, 5.05mL) was added. The mixture was allowed to react at 25°C for 12 hours. The reaction mixture was diluted with 100mL of water at 0°C and extracted with ethyl acetate (100mL x 2). The organic phases were combined, washed sequentially with saturated brine (50mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 022-2. 1H NMR(400MHz, CDCl3)δ8.22(s,1H),7.53(dd,J=3.0,9.1Hz,1H),6.88-6.79(m,1H),6.79-6.73(m,1H),6.40-6.03(m, 1H), 5.37 (d, J=14.6Hz, 1H), 4.66-4.55 (m, 2H), 4.55-4.47 (m, 1H), 4.07-4.01 (m, 1H), LCMS: m / z=472.9, 474.9[M+H] + .

[0511] Step 3:

[0512] 022-2 (1.6 g, 3.38 mmol) and N, N-diisopropylethylamine (1.77 mL, 10.14 mmol) were dissolved in tetrahydrofuran (32 mL), and then O-(7-azabenzotriazole-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate (1.67 g, 4.40 mmol) was added. After stirring for half an hour, B-7 (1.03 g, hydrochloride) was added and stirred at 25 ° C for 1 hour. The reaction solution was diluted with water (30 mL) and extracted with ethyl acetate (20 mL * 3). The organic phases were combined, washed with saturated brine (20 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (PE: EA = 1:0 to 0:1) to obtain 022-3. 1 H NMR(400MHz, CDCl3)δ8.04(s,1H),7.95(br d,J=6.3Hz,1H),7.69(d,J=8.3Hz,2H),7.30(d,J=8.1Hz,2H),7.05-6.98(m,1H),6.97-6.90(m,1H),6. 84(dd,J=2.8,8.4Hz,1H),6.20-5.85(m,1H),5.63(d,J=15.9Hz,1H),5.01(quin,J=6.4Hz,1H),4.60(br d,J=11.9Hz,1H),4.53-4.39(m,2H),4.12-4.06(m,1H),3.99(br d,J=7.5Hz,1H),2.59-2.46(m,2H),2.44(s,3H),2.33-2.21(m,1H),2.20-2.10(m,1H), LCMS: m / z=696.0, 698.0[M+H] + .

[0513] Step 4:

[0514] 022-3 (2.0 g, 2.14 mmol) was dissolved in N,N-dimethylformamide (60 mL), and then potassium carbonate (1.18 g, 8.57 mmol) was added and stirred at 45°C for 8 hours. The reaction solution was diluted with water (30 mL), extracted with ethyl acetate (20 mL*3), and the organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was added to ethanol (8 mL), stirred at 20°C for half an hour, and then filtered. The filter cake was rinsed with ethanol (2 mL) and dried to obtain 022-4. 1 H NMR(400MHz,CDCl3)δ9.03(br d,J=10.4Hz,1H),8.07(s,1H),6.96-6.85(m,2H),6.49(dd,J=4.5,9.0Hz,1H),6.25-5 .89(m,2H),5.04-4.94(m,1H),4.89(q,J=4.3Hz,1H),4.76(d,J=11.9Hz,1H),4.44-4. 29(m,2H),4.24(d,J=15.9Hz,1H),3.10(td,J=6.6,12.8Hz,1H),2.87-2.74(m,1H),2. 28(dd,J=7.8,13.7Hz,1H),1.92(dd,J=7.8,13.6Hz,1H), LCMS: m / z=524.2, 526.2[M+H] + .

[0515] Step 5:

[0516] 022-4 (0.45 g, 0.86 mmol), B-8 (428.0 mg, 2.57 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl) (2'-amino-1,1'-biphenyl-2-yl) palladium (II) (145.3 mg, 0.17 mmol) and cuprous iodide (49.04 mg, 0.26 mmol) were added to acetonitrile (9.0 mL) and methanol (2.25 mL), followed by diisopropylamine (4.51 mL, 31.9 mmol). The mixture was heated to 60°C and stirred for 12 hours under a nitrogen atmosphere. B-8 (142.7 mg, 0.86 mmol) was added and stirred at 60°C for 12 hours. The resulting reaction solution was concentrated under reduced pressure to obtain the crude product of 022-5. LCMS: m / z = 610.2 [M+H] + .

[0517] Step 6:

[0518] 022-5 (0.72 g, 1.18 mmol) was dissolved in tetrahydrofuran (14.4 mL). The temperature was cooled to 0°C, and a solution of ethyl acetate (4 M, 2.88 mL) was added dropwise. The mixture was stirred at 0°C for 1.5 hours. Water (10 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane (10 mL x 3). The resulting organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:0 to 0:1) to obtain 022. Chiral chromatographic column detection [chromatographic column: Chiralpak IH-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 022 was 1.253 minutes, ee = 99.34%, and the retention time of the other isomer was 1.528 minutes. 1 H NMR (400MHz, CDCl3) δ9.06(br d,J=10.4Hz,1H),8.05(s,1H),6.98-6.79(m,2H),6.48(br dd,J=4.3,8.8Hz,1H),6.25-5.94(m,2H),4.98(br d,J=5.9Hz,1H),4.88(br d,J=4.1Hz,1H),4.76(br d,J=11.8Hz,1H),4.44-4.29(m,2H),4.23(br d,J=15.9Hz,1H),3.75-3.29(m,1H),3.15-3.03(m,1H),2.86-2.77(m,1H),2.29(br dd,J=7.6,13.4Hz,1H),1.90(br dd,J=7.6,13.6Hz,1H),1.22-1.12(m,4H), LCMS:m / z=526.1[M+H] + .

[0519] Example 23

[0520] Compound 022 was used as the starting material and 023 was obtained by referring to the synthesis method of the above embodiment. Characterization of 023: Chiral chromatography column detection [chromatographic column: Chiralpak IC-3, 50×4.6mm ID, 3μm; mobile phase A: supercritical carbon dioxide, mobile phase B: ethanol [0.2% NH3 / MeOH (7M)]; the proportion of phase B increased from 5% to 50% in the first 1.2 minutes and was maintained for 1 minute, and then the proportion of phase B decreased from 50% to 5% in the next 0.8 minutes] showed that the retention time of 023 was 1.680 minutes, ee = 99.88%, and the retention time of the other isomer was 1.437 minutes. 1 H NMR(400MHz,CDCl3)δ9.04(br d,J=10.5Hz,1H),8.06(s,1H),6.99-6.80(m,2H),6.47(dd,J=4.4,8.9Hz, 1H),6.31-5.91(m,2H),5.06-4.92(m,1H),4.88(q,J=4.2Hz,1H),4.77(br d,J=11.9Hz,1H),4.45-4.29(m,2H),4.23(br d,J=15.7Hz,1H),3.15-2.98(m,1H),2.88-2.69(m,1H),2.29(dd,J=7.7,13.6Hz,1H),1. 90(dd,J=7.7,13.5Hz,1H),1.48-1.35(m,2H),1.30-1.21(m,2H), LCMS:m / z=528.1[M+1] + .

[0521] Example 24

[0522] Step 1:

[0523] 001-3 (0.3 g, 0.8 mmol) was added to acetonitrile (0.2 mL). The atmosphere was purged with nitrogen three times, followed by the addition of palladium (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]methanesulfonate (67.3 mg, 0.08 mmol) and cesium carbonate (0.52 g, 1.6 mmol). The temperature was slowly raised to 80°C, followed by the addition of a solution of propyne (1 M in tetrahydrofuran, 2.39 mL) in acetonitrile (3 mL). The reaction mixture was allowed to react for 12 hours. After cooling to room temperature, water (5.0 mL) was added to quench the reaction mixture, followed by extraction with dichloromethane (5.0 mL*3). The organic phases were combined, washed sequentially with saturated brine (10.0 mL*3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 024-1. LCMS: m / z = 337.2 [M+H] + .

[0524] Step 2:

[0525] 024-1 (0.13 g, 0.39 mmol) and B-4 (0.19 g, 0.58 mmol) were dissolved in N,N'-dimethylformamide (2.0 mL), followed by the addition of cesium carbonate (0.38 g, 1.16 mmol). The mixture was stirred at 25°C under a nitrogen atmosphere for 2 hours. Water (2.0 mL) was added to the reaction mixture to quench the reaction. The mixture was then extracted with ethyl acetate (10.0 mL x 3). The combined organic phases were washed sequentially with saturated brine (10.0 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 024-2. 1 H NMR(400MHz, CDCl3)δ8.00(s,1H),7.68-7.53(m,1H),7.02-6.91(m,1H),6.90-6.79(m,1H),6.13-5.77(m,2H),4.55-4.36(m,5H),4.28-4.15(m, 2H),4.04-3.93(m,1H),3.91-3.79(m,1H),2.18(s,3H),1.62-1.56(m,3 H),1.41(brs,9H),1.36(brs,3H),1.32(brs,3H); LCMS: m / z=632.3[M+H] + .

[0526] Step 3:

[0527] 024-2 (0.1 g, 0.16 mmol) was added to a mixture of ethanol (2 mL), tetrahydrofuran (1 mL), and methanol (1 mL), followed by the addition of lithium hydroxide (95.8 mg, 4.0 mmol) and allowed to react at 30°C for 24 hours. Water (5 mL) was added to the reaction mixture to quench the reaction, and the pH was adjusted to approximately 5 with 2M hydrochloric acid. The mixture was extracted with ethyl acetate (5 mL x 3). The combined organic phases were washed sequentially with saturated brine (5 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (PE:EA = 1:1) to obtain 024-3. LCMS: m / z = 604.3 [M+H] + .

[0528] Step 4:

[0529] Dissolve 024-3 (55 mg, 91.12 μmol) in dichloromethane (1 mL), then add trifluoroacetic acid (0.3 mL) and react at 20°C for 2 hours. Evaporate the trifluoroacetic acid under reduced pressure to obtain crude 024-4, which was used directly in the next reaction without purification. LCMS: m / z = 504.3 [M+H] + .

[0530] Step 5:

[0531] 024-4 (50.0 mg, 99.31 μmol) was dissolved in dichloromethane (0.1 mL), followed by the addition of N,N-diisopropylethylamine (0.5 mmol, 86.5 μL) and pentafluorophenyl diphenyl phosphate (57.2 mg, 0.15 mmol), and the mixture was stirred at 20°C for 3 hours. 5 mL of water was added to the reaction solution, and the mixture was extracted with dichloromethane (10 mL*3). The organic phases were combined, washed sequentially with saturated brine (20 mL*3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (PE:EA=0:1) and then by preparative high-performance liquid chromatography (column: Waters Xbridge Prep OBD C18 column, 150*40 mm*10 μm; mobile phase: phase A: 10 mM aqueous ammonium bicarbonate solution, phase B: acetonitrile; gradient: phase B: 35% to 65% over 8 minutes) to obtain 024. 1H NMR (400MHz, CDCl3) δ9.20(br s,1H),8.03(s,1H),7.03-6.92(m,2H),6.89-6.81(m,1H),6.19-5.85(m,2H),4.72(br d,J=11.9Hz,1H),4.39-4.18(m,3H),3.98-3.86(m,2H),2.17(s,3H),1.81(s,3H),1.61(s,3H); LCMS:m / z=486.3[M+H] + .

[0532] Example 25

[0533] Step 1:

[0534] 001-3 (0.3 g, 0.8 mmol) was added to acetonitrile (6.0 mL). The atmosphere was purged with nitrogen three times, followed by the addition of (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium (67.3 mg, 0.08 mmol) and cesium carbonate (0.52 g, 1.6 mmol). The temperature was slowly raised to 80°C, followed by the addition of a solution of (triisopropylsilyl)acetylene (535.4 μL, 2.39 mmol) in acetonitrile (6.0 mL). The reaction mixture was allowed to react for 12 hours. The acetonitrile was evaporated under reduced pressure, and the resulting solution was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to afford 025-1. LCMS: m / z = 479.3 [M+H]. + .

[0535] Step 2:

[0536] 025-1 (0.26 g, 0.54 mmol) and B-4 (0.22 g, 0.65 mmol) were dissolved in N,N-dimethylformamide (2.6 mL), followed by the addition of cesium carbonate (0.53 g, 1.63 mmol) and stirring at 20°C for 2 hours. Water (10 mL) was added to the reaction mixture to quench the reaction, followed by extraction with ethyl acetate (10 mL x 3). The combined organic phases were washed sequentially with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 025-2. 1H NMR (400MHz, CDCl3) δppm 8.04(s,1H),7.70-7.56(m,1H),7.00-6.91(m,1H),6.89-6.80(m,1H),6.13-5.78(m,2H),4.53-4.40(m,5H),4.31-4.22(m,1H),4.18(br d,J=9.0Hz,1H),4.00-3.91(m,1H),3.86(br d,J=11.7Hz,1H),1.42-1.38(m,12H),1.37-1.31(m,9H),1.19(s,18H), LCMS: m / z=774.4[M+H] + .

[0537] Step 3:

[0538] 025-2 (0.13 g, 0.17 mmol) was added to a solution of ethanol (2.6 mL), tetrahydrofuran (1.3 mL), and methanol (1.3 mL), followed by a mixed solvent solution of sodium hydroxide (2 M, 2.6 mL) and stirred at 30°C for 24 hours. The reaction mixture was cooled to 0°C and quenched with water (5 mL). The pH was adjusted to approximately 7 with 2 M hydrochloric acid, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed sequentially with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 025-3. LCMS: m / z = 590.3 [M+H] + .

[0539] Step 4:

[0540] Dissolve 025-3 (35.0 mg, 59.4 μmol) in dichloromethane (1 mL), then add trifluoroacetic acid (0.3 mL) and stir at 20°C for 1 hour. Evaporate the trifluoroacetic acid under reduced pressure to obtain crude 025-4, which was used directly in the next reaction without purification. LCMS: m / z = 490.3 [M+H] + .

[0541] Step 5:

[0542] 025-4 (25.0 mg, 51.1 μmol) was dissolved in dichloromethane (0.3 mL), and pentafluorophenyl diphenyl phosphate (29.4 mg, 76.6 μmol) and N,N-diisopropylethylamine (33.0 mg, 255.4 μmol) were added sequentially. The mixture was stirred at 20°C for 3 hours. Water (5 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane (10 mL*3). The organic phases were combined, washed sequentially with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) and then by preparative high-performance liquid chromatography (chromatographic column: Waters Xbridge BEH C18 column 100*30mm*10μm; mobile phase: phase A is 10mM ammonium bicarbonate aqueous solution, phase B is acetonitrile; gradient: phase B increases from 35% to 65% in 8 minutes) to obtain 025. 1 H NMR (400MHz, CDCl3) δ9.19(br s,1H),8.06(br s,1H),7.08-6.72(m,3H),6.23-5.79(m,2H),4.73(br d,J=11.3Hz,1H),4.44-4.17(m,3H),4.05-3.82(m,2H),3.46(br s,1H),1.81(br s,3H),1.62(br s,3H); LCMS: m / z=472.3[M+H] + .

[0543] Example 26

[0544] Step 1:

[0545] 001-3 (0.4 g, 1.06 mmol) was added to acetonitrile (4.0 mL). The atmosphere was purged with nitrogen three times, followed by the addition of (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium (89.8 mg, 0.106 mmol) and cesium carbonate (0.69 g, 2.12 mmol). The temperature was slowly raised to 80°C, followed by the addition of a solution of cyclopropylacetylene (263.9 μL, 3.18 mmol) in acetonitrile (2.0 mL). The reaction mixture was allowed to react for 12 hours. The acetonitrile was evaporated under reduced pressure, and the resulting solution was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to afford 026-1. LCMS: m / z = 363.2 [M+H]. + .

[0546] Step 2:

[0547] 026-1 (0.24 g, 0.66 mmol) and B-4 (0.26 g, 0.79 mmol) were dissolved in N,N-dimethylformamide (4.0 mL), followed by the addition of cesium carbonate (0.65 g, 1.99 mmol) and stirring at 20°C for 2 hours. Water (10 mL) was added to the reaction mixture to quench the reaction, followed by extraction with ethyl acetate (10 mL x 3). The combined organic phases were washed sequentially with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to afford 026-2. 1 H NMR(400MHz, CDCl3)δ7.99(s,1H),7.72-7.47(m,1H),7.00-6.83(m,2H),6.13-5.68(m,2H),4.67-4.33(m,5H),4.3 2-4.08(m,3H),4.02-3.93(m,1H),3.89-3.78(m,1H),1.44-1.31(m,18H),1.01-0.86(m,4H); LCMS:m / z=658.4[M+H] + .

[0548] Step 3:

[0549] 026-2 (0.17 g, 0.26 mmol) was added to a solution of ethanol (3.4 mL), tetrahydrofuran (1.7 mL), and methanol (1.7 mL). A mixed solvent solution of potassium hydroxide (2 M, 3.4 mL) and sodium fluoride (21.7 mg, 0.52 mmol) was then added, and the mixture was stirred at 30°C for 60 hours. Water (10 mL) was added to the reaction mixture to quench the reaction. The pH was adjusted to 3-4 with 2 M hydrochloric acid, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed sequentially with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 026-3. LCMS: m / z = 630.3 [M+H] + .

[0550] Step 4:

[0551] 026-3 (80.0 mg, 127.1 μmol) was dissolved in dichloromethane (1.6 mL), and trifluoroacetic acid (0.5 mL) was added. The mixture was stirred at 20°C for 0.5 h. The trifluoroacetic acid was evaporated under reduced pressure to obtain crude 026-4, which was used directly in the next reaction without purification. LCMS: m / z = 530.3 [M+H] + .

[0552] Step 5:

[0553] 026-4 (67.0 mg, crude product) was dissolved in dichloromethane (1.4 mL), followed by the addition of 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate (98.8 mg, 189.8 μmol) and N,N-diisopropylethylamine (110.2 μL, 632.7 μmol). The mixture was stirred at 20°C for 2 hours. The reaction was quenched by the addition of water (5 mL) and extracted with dichloromethane (10 mL x 3). The organic phases were combined, washed sequentially with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) and then by preparative high-performance liquid chromatography (chromatographic column: Phenomenex Luna C18 column 75*30mm*3μm; mobile phase: phase A is 0.2% formic acid aqueous solution, phase B is acetonitrile; gradient: phase B gradient increases from 25% to 60% within 8 minutes) to obtain 026. 1 H NMR (400MHz, CDCl3) δppm 9.18 (s, 1H), 8.01 (s, 1H), 7.04-6.93 (m, 2H), 6.85 (br dd, J = 4.4, 9.5Hz, 1H), 6.20-5.83 (m, 2H), 4.71 (br d,J=12.0Hz,1H),4.40-4.32(m,1H),4.28(td,J=1.8,12.0Hz,1H),4.22(d,J=15.1Hz,1H),3.99-3.92(m,1H),3.91-3 .83(m,1H),1.81(s,3H),1.61(s,3H),1.33-1.22(m,1H),0.98-0.92(m,2H),0.91-0.85(m,2H); LCMS: m / z=512.3[M+H] + .

[0554] Example 27

[0555] 003-4 (20 mg, 38.0 μmol) and 2-methyl-3-butyn-2-ol (37.1 μL, 380.1 μmol) were dissolved in 1,4-dioxane (0.1 mL). Under nitrogen atmosphere, a pre-prepared solution of bis(acetonitrile)palladium(II) chloride (0.3 mg, 1.14 μmol), cuprous iodide (0.15 mg, 0.76 μmol), tri-tert-butylphosphine (4.61 mg, 2.28 μmol) and N,N-diisopropylamine (6.4 μL, 45.6 μmol) in 1,4-dioxane (0.2 mL) was added and the mixture was heated to 96 ° C for 12 hours. After cooling to room temperature, 2-methyl-3-butyn-2-ol (37.1 μL, 380.1 μmol) and a pre-prepared solution of bis(acetonitrile)palladium(II) chloride (0.3 mg, 1.14 μmol), cuprous iodide (0.15 mg, 0.76 μmol), tri-tert-butylphosphine (4.61 mg, 2.28 μmol), and N,N-diisopropylamine (6.4 μL, 45.6 μmol) in 1,4-dioxane (0.2 mL) were added. The temperature was raised to 96°C and the reaction was allowed to proceed for an additional 12 hours. After cooling to room temperature, the reaction was quenched by the addition of 10 mL of water. The reaction was then extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed sequentially with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative thin-layer chromatography (developing solvent: petroleum ether:ethyl acetate = 1:1), and then separated and purified by preparative chromatography (chromatographic column: Waters Xbridge BEH C18 100*30mm*10μm, mobile phase: phase A: 10mM ammonium bicarbonate aqueous solution, phase B: acetonitrile, phase B gradient increasing from 35% to 65% within 8 minutes). The target eluate was concentrated under reduced pressure and then separated and purified by thin-layer chromatography (developing solvent: petroleum ether:ethyl acetate = 1:1) to obtain 027. Chiral analysis (chromatographic column: Chiralcel OD-3, 150×4.6 mm ID, 3 μm; mobile phase A: supercritical carbon dioxide, mobile phase B: methanol [0.2% NH3 / MeOH (7 M)], gradient: phase B increased from 0% to 50% in the first 3.5 minutes, maintained for 1 minute, and then decreased to 10% within 0.5 minutes) showed ee = 98.9%, Rt = 3.491 minutes, and Rt = 3.079 minutes for its enantiomer. 1H NMR (400MHz, CDCl3) δppm 9.22 (s, 1H), 8.04 (s, 1H), 7.03-6.96 (m, 2H), 6.85 (br dd, J = 4.5, 9.6Hz, 1H), 6.21-5.86 (m, 2H), 4.72 (br d,J=12.0Hz,1H),4.42-4.33(m,1H),4.32-4.26(m,1H),4.23(d,J=15.1Hz,1H),3.99-3.93(m,1H),3.89-3.84(m,1H),1.78(s,3H),1.66(br s,3H),1.65(br s,6H), LCMS: m / z=530.3[M+H] + .

[0556] Biological test data

[0557] Experimental Example 1: In vitro kinase inhibitory activity test

[0558] Compounds against ALK G1202R / L1196M The kinase inhibitory activity tests of TRKB and TNF-α were completed at Hefei Zhongke Puruisheng Biotechnology Co., Ltd.

[0559] Experimental Materials:

[0560] ALK (G1202R / L1196M) Active was purchased from Carna; SRC Substrate was purchased from SignalChem; IGF1R tide was purchased from SignalChem; ADP-Glo ​​Kinase Assay was purchased from Promega; Kinase assay buffer III was purchased from SignalChem; Nivo multi-label analyzer (PerkinElmer).

[0561] Experimental methods:

[0562] (1) ALK (G1202R / L1196M) kinase inhibition test method:

[0563] Reaction system: ALK (G1202R / L1196M) reaction concentration 8.63 nM, ATP concentration 5.0 μM, substrate IGF1 concentration 0.2 μg / μL, ALK (G1202R / L1196M) kinase buffer is 40 mM Tris-HCl (pH 7.5) + 20 mM magnesium chloride + 0.1 mg / mL BSA + 50 μM DTT.

[0564] Detection method: Add 2 μL kinase and 1 μL compound to a 384 plate; add 2 μL substrate / ATP mixture and incubate at room temperature in the dark for 60 minutes; add 5 μL ADP-Glo TM Reagent, incubate at room temperature for 40 minutes; add 10 μL Kinase Detection Reagent, incubate at room temperature for 30 minutes; read the plate on a microplate reader and record the luminescence (set the integration time to 0.5 seconds).

[0565] (2) TRKB kinase inhibition test method:

[0566] The preparation method of the working solution of the test compound is the same as that of ALK kinase. Add 2μL TRKB (0.5ng per well) and 4μL of a mixture of substrate and ATP (5μM ATP, 0.5μM SRC Substrate) to the microplate. The final concentration of the compound is diluted from 10μM to 0.128nM, and the final concentrations of ATP and substrate are 0.25μM and 0.2μg / μL respectively. Subsequent steps are the same as ALK G1202R / L1196M Kinase.

[0567] Reaction system: TRKB reaction concentration 4.47 nM, ATP concentration 5.0 μM, substrate PolyE4Y1 concentration 0.2 μg / μL, TRKB kinase buffer 40 mM Tris-HCl (pH 7.5) + 20 mM magnesium chloride + 2.5 mM manganese chloride + 0.1 mg / mL BSA + 50 μM DTT.

[0568] The detection method is the same as ALK (G1202R / L1196M).

[0569] Data Analysis:

[0570] The raw data were converted into inhibition rate, IC, using the equation (Sample-Min) / (Max-Min)*100%. 50 The value of can be obtained by four-parameter curve fitting (using the log(inhibitor) vs. response - Variable slope mode in GraphPad Prism). The experimental results are shown in Table 1.

[0571] Table 1: Kinase half-maximal inhibitory concentration IC 50 (nM)

[0572] Conclusion: The compounds of the present invention have significant inhibitory activity against ALK kinase mutants, but relatively weak inhibition against TRKB kinase, and have good selectivity.

[0573] Experimental Example 2: Anti-proliferative activity test on Ba / F3 cell lines Ba / F3-EML4-ALK-G1202R / L1196M and Ba / F3-TEL-NTRK2 Experimental Materials

[0574] (1) Cell line (established by Hefei Zhongke Puruisheng Biopharmaceutical Technology Co., Ltd.)

[0575] ALK G1202R / L1196M Cell line: Ba / F3-EML4-ALK-G1202R / L1196M; TRKB cell line: Ba / F3-TEL-NTRK2.

[0576] (2) Reagents

[0577] RPMI 1640: VivaCell brand, product number C3010-0500; fetal bovine serum: VivaCell brand, product number C04001-500;

[0578] Penicillin-streptomycin solution: Gibco, product number 15140-122; CellTiterGlo: Promega, product number G7573;

[0579] Trypan blue: Solarbio, product number C0040; 96-well white plate: Biosharp, product number BS-MP-96W;

[0580] 96-well plate: Beaver brand, item number 40196.

[0581] (3) Instruments

[0582] Cell counter, manufacturer: Count star, model: IC1000; microplate reader, manufacturer: Molecular Devices, model: SpectraMax Paradigm; carbon dioxide incubator, manufacturer: Thermo, model: HERA cell vios 160i.

[0583] (4) Compound information: The compounds were prepared in DMSO at a working concentration of 1 mM.

[0584] Experimental methods

[0585] (1) Cell culture: The cell lines were cultured in an incubator at 37°C and 5% CO2. Cells were passaged regularly and cells in the logarithmic growth phase were used for plating.

[0586] (2) Compound storage plate preparation: Prepare the test compound into a 10 mM solution (Stock Con.) with DMSO; then prepare the compound into a 1 mM solution (Work Con.) with DMSO; take 1 μL of Stock solution and 9 μL of DMSO to prepare 10 μL of Work solution;

[0587] (3) Prepare 1000× compound storage plates (tubes): dilute the compound three-fold with DMSO from 1 μM to the lowest concentration, for a total of 8 concentrations;

[0588] (4) Preparation of 20× compound working solution: Add 98 μL of cell culture medium to a flat-bottomed 96-well transparent plate. Pipette 2 μL of compound from a 1000× compound storage plate and add it to the cell culture medium in the 96-well transparent plate. Add 2 μL of DMSO to the vehicle control. After adding the compound or DMSO, mix thoroughly by pipetting with a dispenser.

[0589] (5) Stain the cells with trypan blue and count the living cells. The cell viability is required to be above 90%, and the cell concentration is adjusted to an appropriate concentration.

[0590] (6) Add 95 μL of cell suspension (2000 cells / well) to each well of the compound test cell plate, and add culture medium without cells (containing 0.1% DMSO) to the Min control wells;

[0591] (7) Compound assay cell plate dosing: 5 μL of 20× compound working solution was added to the cell culture plate. 5 μL of DMSO-cell culture medium mixture was added to the Max control, with a final DMSO concentration of 0.1%;

[0592] (8) Incubate the culture plate in a 37°C, 5% CO2 incubator for 72 hours;

[0593] (9) Follow the instructions of the Promega CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega-G7573) to perform the following operations: melt the CellTiter-Glo buffer and bring it to room temperature; bring the CellTiter-Glo substrate to room temperature; add CellTiter-Glo buffer to a bottle of CellTiter-Glo substrate to dissolve the substrate, thereby preparing the CellTiter-Glo working solution; slowly vortex to fully dissolve; remove the cell culture plate and let it stand for 10 minutes to equilibrate to room temperature; add 50 μL (equal to half the volume of the cell culture solution in each well) of CellTiter-Glo working solution to each well; shake the culture plate on an orbital shaker for 2 minutes to induce cell lysis; let the culture plate stand at room temperature for 10 minutes to stabilize the luminescent signal; detect the luminescent signal on a SpectraMax Paradigm plate reader; and perform the CellTiter-Glo luminescent cell viability assay.

[0594] Data Analysis

[0595] The SpectraMax Paradigm readings were used to obtain the corresponding fluorescence value RLU per well; the cell proliferation inhibition rate (Inhibition Rate) data were calculated using the formula Inhibition Rate (Inh%) = 100-(RLU Drug -RLU Min ) / (RLU Max -RLU Min )*100%. The inhibition rates corresponding to different concentrations of compounds were calculated in Excel, and then the inhibition rate curve was plotted using GraphPad Prism software and related parameters were calculated, including the maximum and minimum inhibition rates of cells, IC 50 The experimental results are shown in Table 2.

[0596] Table 2: Half inhibitory concentration IC 50 (nM)

[0597] Conclusion: The compounds of the present invention have a strong inhibitory effect on Ba / F3-EML4-ALK-G1202R / L1196M cells, a weaker inhibition on Ba / F3-TEL-NTRK2 cells, and have excellent selectivity.

[0598] Experimental Example 3: Antiproliferative Activity Test on 7 Ba / F3 Cell Lines

[0599] The experimental method was the same as that of Experimental Example 2. The seven cell lines used in the test were Ba / F3-EML4-ALK WT, Ba / F3-EML4-ALK-G1202R, Ba / F3-EML4-ALK-L1196M, Ba / F3-EML4-ALK-I1171S, Ba / F3-EML4-ALK-G1269A, Ba / F3-EML4-ALK-F1174C, and Ba / F3-EML4-ALK-F1174C-D1203N. The test results are shown in Table 3.

[0600] Table 3: Half inhibitory concentration IC 50 (nM)

[0601] Conclusion: The compounds of the present invention have potent inhibitory effects on the above 7 cell lines.

[0602] Experimental Example 4: Permeability MDR1 Test

[0603] Purpose of the experiment:

[0604] The permeability and efflux ratio of the test compounds were evaluated using the MDCKII-MDR1 monolayer cell assay system to determine the compound's potential to cross the blood-brain barrier and its potential to be effluxed by the P-gp transporter.

[0605] Experimental methods:

[0606] MDCKII-MDR1 cells (from the Netherlands Cancer Institute) were seeded into 96-well cell plates (from Corning) at a cell density of 2.5 x 10 5 cells / ml, cultured for 7 days to form a copolymerized cell monolayer. The transport buffer is a Hank's balanced salt buffer (pH 7.40±0.05) containing 10mM 4-hydroxyethylpiperazineethanesulfonic acid and 1% BSA (bovine serum albumin). The bidirectional transport of the test compound at a concentration of 2μM was tested, and the concentration of DMSO in the incubation system was controlled below 1%. After addition of the sample, the cell plate was placed at 37±1°C, 5% CO2 and saturated humidity and incubated for 150 minutes. All samples were quantitatively analyzed by LC-MS / MS method. The apparent permeability coefficient (P app , cm / s), efflux ratio (ER) and recovery rate.

[0607] Apparent permeability coefficient (P app ,cm / s) is calculated using the following formula: P app =(dC r / d t )×V r / (A×C0). Where, dC r / d t is the cumulative concentration of the compound at the receiving end per unit time (μM / s); V r is the volume of the solution at the receiving end (the volume of the solution at the apical and basal ends is 0.075 mL and 0.250 mL, respectively); A is the relative surface area of ​​the cell monolayer (0.0804 cm 2 ); C0 is the starting concentration of the test substance at the dosing end (nM) or the peak area ratio of the reference substance.

[0608] The efflux ratio (ER) is calculated using the following formula: ER = P app (BA) / P app (AB). The recovery rate was calculated using the following formula: % recovery rate = 100 × [(V r ×C r )+(V d ×C d )] / (V d × C0). Where C0 is the starting concentration (nM) of the test sample at the dosing end or the peak area ratio of the reference sample; V d is the volume of the dosing end (0.075 mL on the apical side and 0.250 mL on the basolateral side); C d and C r The final concentration (nM) of the test sample at the dosing end and the receiving end or the peak area ratio of the reference sample are shown in Table 4.

[0609] Table 4: MDCKII-MDR1 test results

[0610] Conclusion: The compounds of the present invention are high osmotic and low efflux compounds.

[0611] Experimental Example 5: Evaluation of metabolic stability of liver microsomes

[0612] Experimental Materials

[0613] Liver microsomes: SD rat, mouse, beagle dog, cynomolgus monkey and human liver microsomes were purchased from Corning, Xenotech or BioIVT and stored at -80°C.

[0614] Nicotinamide adenine dinucleotide phosphate (NADPH), reduced, supplier: Chem-impex international, product number: 00616.

[0615] Control compounds: testosterone, diclofenac, propafenone.

[0616] Experimental procedures

[0617] (1) Preparation of working fluid

[0618] Stock solution: 10 mM DMSO solution.

[0619] Working concentration preparation: dilute to 100 μM in 100% acetonitrile (organic phase content: 99% ACN, 1% DMSO).

[0620] (2) Experimental steps

[0621] Prepare two 96-well incubation plates, designated T60 and NCF60. Add 445 μL of microsomal working solution (liver microsomal protein concentration 0.56 mg / mL) to each of the T60 and NCF60 plates. Pre-incubate the plates in a 37°C water bath for approximately 10 minutes.

[0622] After the preincubation period, 5 μL of the test or control compound working solution was added to each well of the T60 and NCF60 plates and mixed thoroughly. The reaction was initiated by adding 50 μL of potassium phosphate buffer to each well of the NCF60 plate. To the T0 stop plate, 180 μL of stop solution (200 ng / mL toluidine and 200 ng / mL labetalol in acetonitrile) and 6 μL of NADPH regeneration system working solution were added. A 54 μL sample was removed from the T60 plate and transferred to the T0 stop plate (T0 sample generation). To initiate the reaction, 44 μL of NADPH regeneration system working solution was added to each well of the T60 plate. A blank plate was filled with only 54 μL of microsome working solution, 6 μL of NADPH regeneration system working solution, and 180 μL of stop solution. Therefore, in the sample of the test or control compound, the final reaction concentration of the compound, testosterone, diclofenac, and propafenone is 1 μM, the concentration of liver microsomes is 0.5 mg / mL, and the final concentrations of DMSO and acetonitrile in the reaction system are 0.01% (v / v) and 0.99% (v / v), respectively. After incubation for an appropriate time (e.g., 5, 10, 20, 30, and 60 minutes), 180 μL of stop solution (containing 200 ng / mL tolbutamide and 200 ng / mL labetalol in acetonitrile) is added to each sample well of the stop plate, and then 60 μL of sample is removed from the T60 incubation plate to terminate the reaction.

[0623] All sample plates were shaken and centrifuged at 3220 rpm for 20 minutes. 80 μL of supernatant from each well was then diluted into 240 μL of pure water for analysis by liquid chromatography-tandem mass spectrometry. The experimental results are shown in Table 5.

[0624] Table 5: Results of liver microparticle metabolic stability test of the compounds of the present invention

[0625] Conclusion: The compounds of the present invention exhibit good metabolic stability in various liver microsomes.

[0626] Experimental Example 6: Cytochrome P450 isoenzyme inhibition activity test

[0627] Purpose of the experiment

[0628] The inhibitory activity of the test compounds on human cytochrome P450 isozymes was determined.

[0629] Experimental methods

[0630] Working solutions of the test compound, standard inhibitor (100× final concentration) and mixed substrate diclofenac were prepared; microsomes (purchased from Corning Inc.) frozen at -80°C were taken out and thawed. 20 μL of the test compound (dissolved in a mixture of dimethyl sulfoxide and methanol in a volume ratio of 1:1, with a final concentration of 0.05 μM) and a standard inhibitor sulfaphenazole methanol solution (final concentration of 3 μM) were added to the corresponding wells. At the same time, 20 μL of the corresponding solvent was added to the inhibitor-free control well (NIC) and the blank control well (Blank). Then, 20 μL of the mixed substrate solution was added to the corresponding wells, except for the Blank well (20 μL of phosphate buffer (PB) was added to the Blank well). Human liver microsome solution was prepared (marked with the date after use and immediately returned to the refrigerator), and then 158 μL of human liver microsome solution was added to all wells. The above sample plate was placed in a 37°C water bath for pre-incubation, and the coenzyme factor (NADPH) solution was prepared immediately. After 10 minutes, 20 μL of the mixed substrate solution was added. NADPH solution was added to all wells, the sample plate was shaken, and then incubated in a 37°C water bath for 10 minutes. At the corresponding time points, 400 μL of cold acetonitrile solution (with 200 ng / mL tolbutamide and labetalol as internal standards) was added to terminate the reaction. After the sample plate was mixed thoroughly, it was centrifuged at 4000 rpm for 20 minutes to precipitate the protein. 200 μL of the supernatant was added to 100 μL of water, shaken, and then analyzed by LC / MS / MS. The results are shown in Table 6.

[0631] Table 6 IC of compounds against P450 isozymes inhibition 50 value

[0632] Experimental conclusion: The inhibitory activity of the compounds of the present invention on CYP2C9 is relatively weak.

[0633] Experimental Example 7: CYP3A4 / PXR Monoclonal Cell Activation Test

[0634] Experimental purpose: To explore the activation effect of the compounds of the present invention on CYP3A4 / PXR monoclonal cells.

[0635] Experimental methods:

[0636] Cell line: HepG2 / CYP3A4 / PXR stable cell line;

[0637] Culture medium: EMEM (Eagle's minimal essential medium) + 10% FBS (fetal bovine serum) + 1% polystyrene (PS) + 0.2 mg / mL hygromycin B;

[0638] HepG2 / PXR / CYP3A4 luciferase reporter gene assay and CTG assay procedures:

[0639] Day 1: Plate cells onto assay plates

[0640] Harvest cells according to the subculture procedure; resuspend the cells in culture medium without hygromycin B and count the cells; adjust the suspension volume using growth medium without hygromycin B, and transfer 45 μL of the cell suspension to each well of a 384-well white-walled microplate (Corning #3707); centrifuge and incubate overnight at 37°C / 5% CO2.

[0641] Day 2: Add compounds to assay plates

[0642] Prepare the reference substance (rifampicin) at a stock concentration of 40 mM in dimethyl sulfoxide (DMSO). Serially dilute rifampicin in DMSO to a maximum dose of 40 mM, with 10 dilutions in 2-fold dilutions. Serially dilute the test compound in DMSO to a maximum concentration of 30 mM, with 10 dilutions in 3-fold dilutions. Dilute rifampicin in a biosafety cabinet using growth EMEM medium without hygromycin B to a maximum concentration of 400 μM, with 10 dilutions. Dilute the test compound in growth EMEM medium without hygromycin B to a maximum concentration of 300 μM, with 10 dilutions. Add 5 μL of 10X rifampicin and the test compound to the assay plate. Therefore, the final rifampicin concentration is up to 40 μM, with 10 dilutions in 2-fold dilutions. For the test compound, the final test compound concentration is 50 μM, with 10 dilutions in 3-fold dilutions. Add 5 μL of 400 μM rifampicin to the positive control wells, for a final rifampicin concentration of 40 μM in the positive control. Add 5 μL of 1% dimethyl sulfoxide to the negative control wells. The final dimethyl sulfoxide concentration is 0.1%. Centrifuge the assay plate (600 rpm, 30 s). Incubate at 37°C / 5% CO2 for 72 hours. Day 5: Luciferase gene assay

[0643] Bring the assay plate and CTG reagent or Bright-lite luciferase reagent to room temperature; add 25 μL / well Bright-lite luciferase reagent or CTG reagent to each well; centrifuge the assay plate (600 rpm, 60 s); measure the luciferase signal on an Envision plate reader or other type of plate reader; export the data and calculate the EC using XLFIT. 50 and CC 50 , the test results are shown in Table 7.

[0644] Table 7 EC of compounds on CYP3A4 / PXR monoclonal cells 50 and CC 50 value

[0645] Experimental conclusion: The compounds of the present invention have no inducing effect on CYP3A4.

[0646] Experimental Example 8: Pharmacokinetic Test

[0647] Purpose of the experiment:

[0648] 7-9 week old male CD-1 mice and SD rats were used as test animals. LC / MS / MS was used to determine the plasma concentrations of the compounds at different time points after a single intravenous (IV) and oral (PO) administration of the compounds to study the pharmacokinetic behavior of the compounds of the present invention in mice and rats.

[0649] Two groups of healthy mice and rats (fasted) were dosed by intravenous injection (IV) and oral gavage (PO), with 2 rats in each group.

[0650] The test compound was mixed with the solvent (10% dimethyl sulfoxide + 10% polyethylene glycol (15)-hydroxystearate + 80% water), vortexed and sonicated to prepare a 0.5 mg / mL clear solution. The intravenous dose for mice or rats was 1.0 mg / kg.

[0651] The test compound was mixed with a solvent (0.5% sodium carboxymethyl cellulose + 1% sorbitan monooleate polyoxyethylene ether), vortexed, and sonicated to prepare a 0.5 mg / mL homogeneous suspension containing particles with a pH of 7.0. The oral gavage dose for mice was 5.0 mg / kg, and the oral gavage dose for rats was 3.0 mg / kg.

[0652] After administration, whole blood was collected at 0.083 h, 0.25 h, 0.5 h, 1.0 h, 2.0 h, 4.0 h, 8.0 h, 12.0 h, and 24.0 h to prepare plasma. Drug concentrations were analyzed by LC-MS / MS, and pharmacokinetic parameters were calculated using Phoenix WinNonlin 6.3. The experimental results are shown in Tables 8 and 9:

[0653] Table 8: Pharmacokinetic test results in mice

[0654] Table 9 Pharmacokinetic test results in rats

[0655] Conclusion: The compounds of the present invention have excellent pharmacokinetic properties in various genera.

[0656] Experimental Example 9: In vivo pharmacodynamics test in mice

[0657] In vivo efficacy experiments were performed on BALB / c nude mice subcutaneously implanted with Ba / F3 EML4-ALK G1202R / L1196M xenografts (CDX).

[0658] Female BALB / c nude mice, 6-8 weeks old, weighing approximately 18-22 g, were purchased from Shanghai Weitong Lihua Laboratory Animal Co., Ltd. (130 mice) for this study. Mice were maintained in a specialized pathogen-free environment in single ventilated cages (5 mice per cage). All cages, bedding, and water were disinfected before use. All animals had free access to food and drink.

[0659] Each mouse was implanted with Ba / F3 EML4-ALK G1202R / L1196M tumor cells (cell inoculation volume: 1x10 6 / 0.1 ml Dulbecco's phosphate-buffered saline) for tumor growth. Experiments were initiated when the average tumor volume reached approximately 170-200 mm³. Compound Group: Test compounds were dissolved in a vehicle (0.5% sodium carboxymethylcellulose / 1% sorbitan monooleate polyoxyethylene ether / water) and administered orally by gavage twice daily. Control Group: Vehicle was administered orally by gavage twice daily at a volume of 10 mL / kg.

[0660] Tumor size was measured every 2 days using a two-dimensional caliper, and tumor volume (V, mm 3 ) and tumor growth inhibition (TGI, %). The calculation formula is as follows:

[0661] V=0.5a×b 2 , where a and b are the long and short diameters of the tumor, respectively;

[0662] If TV t ≥TV0, TGI=100%×(1-(TV t -TV0) / (CV t -CV0);

[0663] If TV t <TV0, TGI = 100% × (2-TV t / TV0);

[0664] Among them, TV t is the average tumor volume of animals after compound treatment, TV0 is the average tumor volume of animals before compound treatment, CV t CV0 is the average tumor volume of the control group before vehicle treatment.

[0665] The experimental results showed that compared with the control group, the tumor growth rate was significantly slowed down after administration of the compound of the present invention, and complete tumor shrinkage (TGI=200%) was achieved with good dose correlation.

[0666] Conclusion: The compounds of the present invention exhibit good in vivo efficacy.

Claims

1. A compound represented by formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, in, is a single bond or a double bond; T6 and T7 are independently selected from C and N, and are not C or N at the same time; L1 is selected from CH2 and C(═O); L is divided by 2 R a Substituted C 1-4 alkyl; R1 is selected from O, S and NR4; R2 is selected from F, Cl, Br, I, OH, NH2, CN, C 1-4 Alkylamino, -NH-C(O)-C 1-4 Alkyl, C 1-4 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl and C 3-6 Cycloalkyl, the C 1-4 Alkylamino, -NH-C(O)-C 1-4 Alkyl, C 1-4 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl and C 3-6 The cycloalkyl group is optionally substituted by 1, 2 or 3 R d replace; Each R3 is independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R b replace; R4 is selected from OH, CN and -(OCH2CH2) n -C 1-3 Alkoxy; n is 0 or 1; Ring A is selected from phenyl, 5-6 membered heteroaryl and C 5-6 Cycloalkenyl, the phenyl, 5-6 membered heteroaryl and C 5-6 The cycloalkenyl group is optionally substituted by 1, 2 or 3 R c replace; Each R a are independently selected from H, F, Cl, Br, I, OH and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R; Or, 2 R a The carbon atom connected to it forms C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl, the C 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 R; Each R b Each independently selected from H, F, Cl, Br, I and OH; Each R c are independently selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens; Each R d are independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted with 1, 2 or 3 R; Each R is independently selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

2. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R is independently selected from H, F, OH, methyl and methoxy.

3. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R a are independently selected from H, F, CH3 and CF3; or, 2 R a The carbon atom to which it is attached forms a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl or N-methylpyrrolidinyl group.

4. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R c are independently selected from H and F.

5. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R d Each of the following is independently selected from H, F, Cl, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl, oxhexacyclohexyl, piperidinyl and morpholinyl, and the methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, oxolanyl, pyrrolidinyl, oxhexacyclohexyl, piperidinyl and morpholinyl are independently selected from 1, 2 or 3 R.

6. The compound according to claim 1 or 3, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: L is selected from Alternatively, L is selected from 7. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R2 is C 2-5 Alkynyl, the C 2-5 The alkynyl group is optionally substituted with 1, 2 or 3 R d Substituted; or, R2 is selected from Said are independently optionally substituted by 1, 2 or 3 R d Substituted; or, R2 is selected from 8. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R3 is independently selected from H, CH3 and CHF2.

9. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from Alternatively, the structural unit Selected from Alternatively, the structural unit Selected from 10. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from 11. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Ring A is selected from phenyl and pyridyl, wherein the phenyl and pyridyl are independently optionally substituted by 1, 2 or 3 R c Substituted; or, Ring A is selected from 12. The compound according to any one of claims 1 to 11, its stereoisomer or a pharmaceutically acceptable salt thereof is selected from: in, R2, R3, L and ring A are as defined in any one of claims 1 to 11; When R3 is not H, the carbon atom with "*" is a chiral carbon atom, which exists in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.

13. The compound according to claim 12, its stereoisomer or a pharmaceutically acceptable salt thereof is selected from: in, R2, L and ring A are as defined in claim 12.

14. The compound of formula (II-3) according to claim 12, its stereoisomer or a pharmaceutically acceptable salt thereof, which is selected from: in, T8 is selected from CH and N; L is selected from C 1-4 Alkyl and C 3-6 Cycloalkyl, the C 1-4 Alkyl and C 3-6 The cycloalkyl group is optionally substituted with 1 or 2 F groups independently; R c Selected from H, F, Cl, Br, I and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 F groups; R d Selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted with 1, 2 or 3 R; Each R is independently selected from H, F, OH, methyl and methoxy; The carbon atom with "*" is a chiral carbon atom, which exists in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.

15. The compound according to claim 14, its stereoisomer or a pharmaceutically acceptable salt thereof is selected from: in, R c , R d , T8 and L as defined in claim 14.

16. The following compound, its stereoisomer or its pharmaceutically acceptable salt, 17. The compound according to claim 16, its stereoisomer or a pharmaceutically acceptable salt thereof, which is selected from:

18. Use of the compound according to any one of claims 1 to 17, its stereoisomer or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating ALK inhibitor-related diseases.

Citation Information

Patent Citations

  • Substituted chiral diaryl macrocyclic compound as TRK inhibitors

    CN113336774A

  • Macrorings for treatment of disease

    CN114929710A

  • Macrocyclic kinase inhibitors and their use

    WO2019126122A1

  • Macrocycles for use in treating disease

    WO2020257165A1

  • Novel substituted macroheterocyclic compounds and use thereof

    WO2023179600A1